Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies

Aidong Yuan, Ralph A. Nixon

Frontiers in Neuroscience · 2021 · Review · CC BY

doi:10.3389/fnins.2021.689938

Abstract

Biomarkers of neurodegeneration and neuronal injury have the potential to improve diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy. Neurofilament proteins (NfPs) are well suited as biomarkers in these contexts because they are major neuron-specific components that maintain structural integrity and are sensitive to neurodegeneration and neuronal injury across a wide range of neurologic diseases. Low levels of NfPs are constantly released from neurons into the extracellular space and ultimately reach the cerebrospinal fluid (CSF) and blood under physiological conditions throughout normal brain development, maturation, and aging. NfP levels in CSF and blood rise above normal in response to neuronal injury and neurodegeneration independently of cause. NfPs in CSF measured by lumbar puncture are about 40-fold more concentrated than in blood in healthy individuals. New ultra-sensitive methods now allow minimally invasive measurement of these low levels of NfPs in serum or plasma to track disease onset and progression in neurological disorders or nervous system injury and assess responses to therapeutic interventions. Any of the five Nf subunits – neurofilament light chain (NfL), neurofilament medium chain (NfM), neurofilament heavy chain (NfH), alpha-internexin (INA) and peripherin (PRPH) may be altered in a given neuropathological condition. In familial and sporadic Alzheimer’s disease (AD), plasma NfL levels may rise as early as 22 years before clinical onset in familial AD and 10 years before sporadic AD. The major determinants of elevated levels of NfPs and degradation fragments in CSF and blood are the magnitude of damaged or degenerating axons of fiber tracks, the affected axon caliber sizes and the rate of release of NfP and fragments at different stages of a given neurological disease or condition directly or indirectly affecting central nervous system (CNS) and/or peripheral nervous system (PNS). NfPs are rapidly emerging as transformative blood biomarkers in neurology providing novel insights into a wide range of neurological diseases and advancing clinical trials. Here we summarize the current understanding of intracellular NfP physiology, pathophysiology and extracellular kinetics of NfPs in biofluids and review the value and limitations of NfPs and degradation fragments as biomarkers of neurodegeneration and neuronal injury.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

It is widely accepted that the pathophysiology underlying many neurodegenerative disorders, such as Alzheimer’s disease (AD), originates many years prior to clinical symptoms. AD evolves through three stages – an early, preclinical stage with no detectable symptoms; a middle stage of mild cognitive impairment; and a late stage marked by symptoms of dementia. The lack of success in identifying treatments that cure AD or alter its progression has been attributed in part to the implementation of candidate treatments at a disease stage that is too advanced to blunt the disease triggering mechanism(s) or halt early progression before momentum builds to irreversible levels. There is a growing need for reliable non-invasive blood-based biomarkers for AD that can facilitate diagnosis, predict disease progression, and provide evidence of disease modification.

Neurofilament proteins (NfPs) appeared in the last few years as the most promising blood biomarkers of neuroaxonal integrity or damage. Nfs are classified as a type IV class of intermediate filaments (IFs) specific to neurons. They are protein polymers measuring 10 nm in diameter and many micrometers in length. Together with microtubules (25 nm) and microfilaments (7 nm), they form the neuronal cytoskeleton. Much interest in the field has been recently focused on the detection of NfPs and degradation fragments released from neurons into blood as surrogate markers of neuronal damage in neuropathic states. The rationale for NfPs and fragments as biomarkers of neuronal damage is that they are not only responsive to neuronal injury but are also prominent components of abnormal intraneuronal aggregates in varied neurodegenerative diseases, including AD, dementia with Lewy bodies (DLB), Parkinson’s disease (PD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), multiple sclerosis (MS), giant axonal neuropathy (GAN) and toxic neuropathies. Although amyloid-beta and tau proteins are widely regarded as useful diagnostic biomarkers of AD, tau proteins increase only in specific neurodegenerative diseases such as AD and unaltered in other neurological diseases that are clearly neurodegenerative, such as tau-negative FTD caused by granulin or C9orf72 mutations where, by contrast, CSF and serum neurofilament light chain (NfL) fragment levels are more than 8 times higher in patients than in pre-symptomatic carriers or healthy controls. Furthermore, in Huntington disease (HD), CSF NfL fragment levels correlate more strongly with disease progression than do CSF tau levels. Moreover, studies using a stable isotope labeling method to investigate tau metabolism demonstrate that the production rate of tau positively correlates with the amount of amyloid plaques, suggesting that increased tau levels in AD could be due to elevated transcription, synthesis or secretion from neurons in response to amyloid-beta pathology rather than reflect actual neurodegeneration. Thus, as general neuronal integrity markers, NfPs and their fragments may be more sensitive to neurodegeneration than is tau.

In individuals with inherited forms of AD, levels of NfL fragments in blood may be altered 22 years before symptoms begin. NfL responds more sensitively to subclinical cognitive decline than amyloid-beta or tau. Moreover, mean NfL fragment plasma levels increased 3.4 times faster in subjects who developed AD compared to those who remained dementia-free in a trajectory analysis of 4444 non-demented participants in the Rotterdam study at baseline and up to 14 years follow-up. In this review, we summarize the current understanding of NfPs and fragments as biomarkers in neurodegeneration and neurological injuries and draw attention to important unanswered questions.

The Physiological Basis of Neurofilament Proteins as Biomarkers of Neuronal Structural Integrity

For a blood-based biomarker to reflect the structural integrity of neurons in human brains, it has to be a structural constituent of the neuron, impacted by the neuropathological process, and easily detectable in blood. The composition of intermediate filament subunits in neurons varies depending on the nerve cell type and stage of development (Figure 1). At the earliest stage of embryonic development, neural stem cells express nestin (NES), a type VI intermediate filament protein that is down-regulated after differentiation and replaced by cell type-specific intermediate filament proteins. Vimentin (VIM), a type III intermediate filament protein of mesenchymal cells, is also transiently co-expressed with nestin in precursor nerve cells. VIM is gradually replaced by peripherin (PRPH), alpha-internexin (INA), neurofilament medium chain (NfM), and NfL during embryonic development. Neurofilament heavy chain (NfH) chain expression is low in developing neurons and increases postnatally.

Mature mammalian neurons usually express five different NfPs: NfL, NfM and NfH chains, as well as INA and PRPH. In mature neurons in the CNS, Nfs are generally composed of NfL, NfM, NfH, and INA, whereas, in the peripheral nervous system, they mainly consist of NfL, NfM, NfH and PRPH. Like all IF proteins, NfPs all share a common alpha-helical rod domain that assembles to form a filament backbone, flanked by variable amino and carboxy-terminal domains that regulate polymer assembly and interactions. NF heteropolymer assembly starts with the formation of NfP dimers and antiparallel aggregation of these dimers leads to formation of tetramers which are thought to be the basic subunit of NFs during assembly and usually consist of NfL and one or more of the other Nf proteins. NfPs of mature neurons in vivo are mainly stable polymers and the pool of soluble NfP is small.

Neurofilament proteins are mainly synthesized in the cell body and transported as hetero-oligomeric assemblies and short filaments into axons and dendrites to establish a highly stable regionally specialized NF network. Nf mRNAs are also transported out of cell bodies into dendrites, spines, and axons and localized NfP synthesis in these cytoplasmic extensions is used to spatially and temporally regulate their protein content in these subcellular domains. NfPs can be proteolyzed by calpains, the proteasome, and autophagy into many smaller degradation products.

The Neuropathological Basis for Neurofilament Proteins as Biomarkers

Biochemical, genetic, and animal model evidence implicates NfPs as a pathogenic culprit playing primary or secondary roles in nervous system diseases. NfPs are involved in the pathophysiological processes underlying many states of neurological injury and neurodegeneration, reflecting changes in structural integrity and abnormal accumulation or maldistribution of NfPs.

Animal Studies

Proper levels of NfPs are important for the normal functions of nervous systems in animals. Absence of NfL from neurons reduces axon diameters and causes sensorimotor and cognitive impairments in quails and mice. Single deletion of NfM, NfH or PRPH in mice can lead to age-related atrophy of motor axons, decrease in conduction velocity and reduced numbers of unmyelinated sensory axons, respectively. Deletion of INA in the absence of NfL or both NfL and NfH results in reduced transport of NfM into axons. Overexpression of NfL, NfM, NfH or PRPH in animals can produce neuropathology of motor neuron diseases while overexpression of INA leads to motor coordination deficits. In addition to the importance of NfP levels, expression of an NfL mutation in mice which causes human disease also leads to motor neuropathology and phenotype of CMT probably due to disruption of Nf assembly and transport, and abnormal Nf accumulation.

Human Studies

Clinical studies demonstrate presence, normal structure and assembled network of NfPs are critical for human health. NfL loss of function mutations in cases of human neuropathy which cause markedly lowered NfL protein levels reduce axon diameters and cause sensorimotor and cognitive impairments in humans. NfL and NfH mutations can cause Nf accumulation in CMT type 2E/1F/CMTDIG and CMT2CC. In AD, NfPs are integral components of neurofibrillary tangles (; Figure 2) and NfH and NfM are 4–8-fold more phosphorylated than normal. In PD, Lewy bodies contain NfPs and a cage-like Nf structure encapsulates Lewy bodies. In Nf inclusion disease, a form of FTD, prominent aggregations of NfPs, especially INA, are the neuropathologic hallmark of the condition. Abnormal NfP accumulations are also a hallmark pathologic feature of ALS. In MS, increased expression of phosphorylated NfH (pNfH) is observed in spinal motor neuron perikarya and Nfs accumulate excessively in axons in GAN.

Recent Technology Breakthroughs for the Reliable Detection of Neurofilament Proteins in the Peripheral Circulation

Low levels of NfPs are constantly released from neurons into CSF and blood under physiological conditions and rise above normal in pathological states.

first tested NfPs as possible biomarkers using enzyme-linked immunosorbent assay (ELISA) with polyclonal rabbit antisera specific against the individual NfPs and showed that CSF NfL levels were increased in patients with ALS and AD compared to controls. However, the sensitivity of ELISA and the later developed electrochemiluminescence (ECL) immunoassay does not allow small, disease-related changes to be reliably detected in peripheral circulation. In 2010, single-molecule enzyme-linked immunosorbent assay (Simoa) was initially described which later enabled reliable quantification of NfL in serum or plasma samples using NfL-specific monoclonal antibodies (mAb47:3). More recently, Meso Scale Discovery, immunomagnetic reduction technologies and the Ella platform based on microfluidic channels have also been developed to detect low NfP levels in blood.

Neurofilament Proteins in Exosomes

The fact that plasma NfL levels are enriched in neuron-derived exosomes compared to total exosomes isolated from blood in healthy individuals suggests the NfPs are released from neurons at least in the form of exosomes (Figure 3). Moreover, plasma neuron-derived exosomes contain about 74-fold more NfL than plasma astrocyte-derived exosomes, which have only negligible amounts. NfP-containing exosomes or NfPs or degradation fragments released into the extracellular space may be eliminated from the CNS along intramural peri-arterial drainage pathway.

Neurofilament Protein Forms in Peripheral Circulation

Identity of the NfL forms in plasma exosomes is still unclear but a 22 kDa NfL degradation fragment has been revealed with an anti-NfL antibody and shown to be increased in ALS patients. Also identified are a 30 kDa fragment of NfL in Nf-containing aggregates from human blood and a 10 kDa fragment of NfL in mouse CSF. Since no full length NfL has been ever reported in CSF or blood, the detected Simoa signal is, therefore, NfL immunoreactivity or NfL breakdown product. By contrast, full length (200 kDa) or oligomeric NfH were predominant in CSF and blood. Recent studies also suggest full length (150 kDa) or trimeric NfM (450 kDa) in blood. A comprehensive list of widely used capture and detection antibodies to NfPs in ELISA is shown in Table 1.

Neurofilament Light Chain Levels in Normal Individuals

Intracellular NfPs have long half-lives ranging from 55 days in axons to 64–72 days at synapses, indicating their slow turnover rates inside neuronal compartments. Upon release into the extracellular space, serum or plasma NfL levels in healthy individuals are about 2.5% of the levels in CSF and correlate highly with the 40-fold higher NfL concentrations in CSF with typical R values ranging from 0.6 to 0.7, suggesting that most of the NfL signal in blood is CNS-derived and could be used as a proxy measure for CSF NfL levels. The NfL levels in blood are most often tested in serum and less frequently in EDTA-plasma with serum levels slightly higher than in plasma. Either specimen type is acceptable, however, when used in either research or clinical setting a single specimen should be selected for use. Plasma NfL levels measured in the morning may be more than 10% higher than those measured in the evening, suggesting that synaptic remodeling during sleep might alter NfL kinetics. CSF NfL levels in healthy females are about 20% lower than levels in healthy males although the reverse was true in an ALS cohort. Concentrations of CSF and serum NfL increase with age in healthy controls with an increase in adult control serum NfL levels of 2.2% per year of age. These increases accompany hippocampal atrophy in cognitively healthy older adults, which has suggested possible AD-independent, age-expected hippocampal decline. However, younger children have higher serum NfL levels than older children reaching the lowest level between the age of 10 and 15 years, then increasing in a linear fashion until the age of 60 years and accelerating non-linearly afterward. There are various proposed bases for serum NfL elevation in aging, including subclinical senescence with greater neuronal apoptosis and increased disruption of blood-brain barrier. Levels of serum NfL may also be affected by race, systolic blood pressure, decreased renal function, glycemic control measured by hemoglobin A1C and pregnancy. The multiplicity of influences on these levels prompts caution in controlling stringently for confounding variables in clinical studies.

Contribution of Neurofilament Proteins or Fragments From Different Neuronal Compartments

Besides calpains, the proteasome and autophagy, other non-specific proteases, including cathepsin D and caspases 6 and 8 can also trigger Nf turnover and generate Nf peptides. Nf assembly confers significant proteolytic resistance to Nf subunits: deletion of three Nf subunits leads to degradation of the fourth subunit. Phosphorylation also protects Nfs against proteolysis. NfPs or their degradation fragments are released into biofluids following any damage to nervous system. Therefore, they are neither able to determine brain region specific alterations nor differentiate disease specific pathophysiological process.

Mechanisms for Neurofilament Protein and Fragment Release From Neurons

The exact mechanisms governing NfP release into biofluid are not fully understood. Release of NfPs or fragments from neurons may be a direct passive consequence of the loss of membrane integrity or may follow the known pathways for active secretion of other neuronal peptides and proteins. Intracellular endosomal organelles known as multivesicular bodies may play critical roles in the release of peptides. This may happen though “back-fusion” events and budding from the plasma membrane to generate micro-vesicles or through release of smaller endosomally derived exosomes. Levels of NfL signals in isolated neuron-derived exosomes accounting for a small percentage of total NfL concentration in plasma suggest that active secretion is at least one of the mechanisms for NfP release from neurons. After release from neurons, some NfPs and fragments can be degraded and cleared by varied extracellular proteinases and microglia and these processes may even further generate the fragments from a larger form. Pathways for degradation could be differentially critical in the context of healthy, injured or chronically damaged neurons. Expression of NfP genes is not elevated in ALS and neither NfP gene nor protein expression is elevated in AD, suggesting that the increased NfP signal in biofluids is not due to a compensatory overproduction.

Major Determinants of Neurofilament Protein and Fragment Levels in Cerebrospinal Fluid and Blood

Studies have linked NfP levels in blood to changes in white matter, gray matter, or both, yielding a confusing picture of what variables dictate the highly variable levels found in different disorders. Some likely determinants of blood/CSF levels, however, include the composition of the diseased or injured area (relative abundance of large caliber axons that have high Nf-content) and size of the damaged region. NfL and NfH content in spinal cord is several fold higher than in corpus callosum and at least 10-fold higher than in cortex. Accordingly, a spinal cord injury released about 12-fold more NfH into blood than a brain injury of comparable size. Demyelinating damage to CNS axons associated with clinical or MRI (magnetic resonance imaging) disease activity in MS can cause a spike of more than 20-fold in the levels of serum NfL which may be lowered with effective treatment. Only about 20% of the NfL fragment present in blood comes from neuron-derived exosomes so the extent of loss of membrane integrity affecting NF-rich axons, or even to a lesser extent synapses, is likely the major determinant of NfP and fragment levels in CSF and blood. In a limited region of involvement as in the substantia nigra pars compacta in PD, NfL fragment level increases in CSF and serum are modest. By contrast, in FTD/ALS, widespread degeneration of large caliber Nf-rich axonal fibers in the spinal cord and brain results in one of the highest elevations of NfP and fragment blood levels among neurodegenerative diseases. More studies are warranted to determine the relative gray and white matter contributions to NfP and fragment levels in biofluids at different stage of a specific disease.

Mechanisms of Neurofilament Protein or Peptide Trafficking Between Brain and Blood

Since the main source of serum NfPs is the CNS, it is not fully clear how NfPs traffic between parenchymal, CSF and blood compartments. NfPs or their degradation fragments could also follow the apparent general pathways by which molecules such as amyloid-beta peptides pass from the interstitial fluid (ISF) of the brain into CSF and blood. Soluble metabolites or peptides from cells in most organ are absorbed directly into the blood or drain via lymphatic vessels to regional lymph nodes. Soluble tracers such as serum albumin injected into ISF of the brain drain to cervical lymph nodes along the walls of cerebral arteries through intramural peri-arterial drainage pathway (IPAD) including initially along basement membranes that surround capillaries and then along the basement membranes between smooth muscle cells in the tunica media of intracerebral and leptomeningeal arteries. About 85% of a tracer injected into the cerebral hemispheres passes to cervical lymph nodes via IPAD while only 10–15% passes into the CSF. Future studies need to measure the proportion of NfPs and degradation fragments released from neurons that reaches the CSF. Drainage of CSF into lymphatic vessels of the nasal mucosa via the cribriform plate appears to be a major lymphatic drainage pathway and may also include dural lymphatics. The glial-lymphatic or glymphatic pathway is recently identified in rodent brain, which sub-serves the flow of CSF into the brain along perivascular spaces and then into the brain interstitium facilitated by aquoporin-4 water channels. This pathway then directs flow toward the venous perivascular and perineuronal spaces, ultimately clearing solutes from neuropil into meningeal and cervical lymphatic drainage vessels.

Dynamics of Extracellular Neurofilament Proteins and Fragments

In acute neurological diseases with a known timepoint for neuronal or axonal damage such as traumatic brain injury (TBI), stroke and MS, CSF and serum NfP signals increased over a few days and remained elevated over many months. It may be difficult to investigate the dynamics of CSF and serum NfPs in chronic neurodegenerative diseases such as AD and PD without treatments that can cure them. Because it is suggested that serum NfL fragments may be cleared by the kidneys, renal function ought to be considered when interpreting serum NfL levels.

Neurofilament Proteins as Biomarkers in Animal Models of Neurological Diseases

Increased levels of plasma NfL have been observed in mouse models of PD A53T- alpha-synuclein, tauopathy P301S-Tau and AD APP/PS1 (amyloid precursor protein/presenilin 1). Increases in NfL in CSF and blood coincide with the onset and progression of the corresponding proteopathic lesions in brain. Experimental induction of alpha-synuclein lesions increase blood NfL levels, while blocking the development of amyloid-beta lesions attenuates NfL increases. Prolonged expression in mice of p25 (the calpain-mediated truncated product of p35, the regulatory subunit of Cdk5 – cyclin-dependent-like kinase 5) causes severe synaptic and neuronal loss and brain atrophy which are accompanied by cognitive deficits. In these inducible CamKII-TetOp25 transgenic mouse models of neurodegeneration, serum NfL levels increase after induction of neurodegeneration by switching on p25 transgene expression via removal of doxycycline but do not increase further if induction is stopped by switching off p25 expression. Increased levels of serum NfL correlate with induced neuronal damage in the cortex and hippocampus of CamKII-TetOp25 mice, indicating that NfL levels mirror the ongoing neurodegeneration and neuronal loss and may be used as a dynamic biomarker of neurodegeneration. In HD R6/2 mice, increased levels of NfL in CSF and serum is associated with neurodegeneration and disease severity. In 304Q knock-in spinocerebellar ataxia type 3 (SCA3) mouse model, serum NfL and pNfH are elevated at the pre-symptomatic stage of 6 months of age and correlate with ataxin 3 aggregation and Purkinje cell loss in the brain. Increased CSF pNFH levels were also observed in horses with equine neuroaxonal dystrophy/degenerative myeloencephalopathy. Plasma pNfH levels also closely reflect later stages of disease progression and therapeutic response in the SOD1 (superoxide dismutase 1) G93A mouse model of ALS. Recently, serum NfL concentration in sheep with prion disease was more than 15 times higher than that found in control samples. More recently, plasma NfL levels were also reported to reflect disease severity in mice inoculated with prions and fell significantly in antisense oligonucleotide-treated mice compared to the immediate pre-dose timepoint, suggesting a reversal of pathology driving the 53% increase in survival time.

Neurofilament Proteins as Biomarkers in Animal Models of Neurological Injuries

Following experimental spinal cord injury (SCI) in adult rats, serum pNfH showed an initial peak of expression at 16 h and a second peak at 3 days while no serum pNfH is detectable in sham control animals. The maximum level of pNfH in these SCI experiments was 250 ng/ml pNfH in the 3–5 day post-injury period following injury. Serum pNfH showed a similar trajectory in TBI in adult rats but the average peak level of expression of serum pNfH was only about 20 ng/ml, much lower than that seen in the SCI model. Recent studies found serum NfL levels were substantially elevated at all acute and subacute time-points after a single mild TBI (mTBI), peaked at 1-day, and remained elevated 14-days post-injury. Increased serum NfL levels were also mTBI dose-dependent and correlated with the degree of sensorimotor impairment. In more recent studies using an experimental rat model of blast-induced TBI, pNfH levels increased at 24 hr, returned to normal levels at 1 month, but increased again at 6 months and 1 year post-blast exposure. Moreover, the changes in CSF pNfH correlate with pNfH levels in brain regions and with neurobehavioral function in the rats.

Neurofilament Proteins as Biomarkers in Neurological Diseases

Cerebrospinal fluid or serum NfL and pNfH have been widely studied as biomarkers in a number of neurological diseases (Table 2) or conditions directly or indirectly affecting central and peripheral nervous systems (Table 3). NfPs are not only elevated in neurological diseases but may also track disease progression. Different subunits might reflect different neurodegenerative processes. In addition to commonly used NfL and pNfH, some studies also found potential values of other Nf subunits, i.e., NfM, INA and PRPH as biomarkers in CSF or serum in neurological diseases or injuries.

Multiple Sclerosis

Patients with MS have up to 60% axonal loss at all spinal levels involving all fibers regardless of their diameter. The concentrations of CSF and serum NfPs represent the degree of axonal loss and therefore, could be a biomarker of MS disease activity. Accordingly, CSF NfL levels in relapsing MS were 3-fold higher than in healthy controls (951.8 vs. 284.4 pg/ml) and associated with relapse and cortical lesions. Serum NfL levels was first reported to be increased in early relapsing MS and correlated with MRI measures of disease severity using an electro-chemiluminescence assay. This finding of serum NfL as a biomarker of MS disease activity was later substantiated with higher sensitivity Simoa digital immunoassay. Increased levels of serum NfL are also associated with MS brain T2 lesion load. A recent study showed that serum NfL levels were associated with T1, T2 and gadolinium-enhancing lesion volumes at baseline and higher serum levels of NfL at baseline were associated with greater atrophy of the whole brain, gray matter and deep gray matter nuclei in the long term. Serum NfL may also detect MS disease activity that escapes detection in routine MRI. The levels of serum NfL increased 6 years before clinical MS onset, indicating MS may have a prodromal phase lasting several years and that neuronal damage occurs already during this phase. After clinical onset, a 1-point Expanded Disability Status Scale (EDSS) increase corresponds to an serum NfL increase of about 14%.

Serum NfL concentrations have been used to assess disease progression in MS. Clinically isolated syndrome (CIS) is one of the MS disease courses and refers to a first episode of neurological symptoms that last at least 24 h and is caused by inflammation or demyelination of in the CNS. Elevated NfL levels in both pediatric and adult patients with CIS have been reported to be associated with a shorter time to clinically definite MS diagnosis independent of other prognostic factors. In patients with confirmed relapsing or progressive MS, baseline serum NfL can predict short-term outcomes including clinical and cognitive performance. Serum NfL levels sampled within the first 5 years of MS symptom onset was shown to independently predict long-term worsening EDSS score and risk of developing progressive MS in patients followed longitudinally for 15–26 years. Notably, patients with serum NfL levels less than 7.62 pg/ml were 7.1 times less likely to develop progressive MS.

Serum/plasma or CSF NfPs have potential utility for assessing treatment efficacy in single patients and beginning at an earlier stage in the disease course. Treatment with any disease-modifying therapy in MS has been reported to be associated with significantly lower serum NfL levels compared to untreated individuals, proving that CSF or serum/plasma NfL is a therapeutic response biomarker in MS that may be related to consequent prevention of ongoing neuronal damage.

Fingolimod significantly reduced plasma NfL levels after 6 months and until the end of the studies (24 months). Similarly, CSF NfL and NfHSMI35 levels were significantly lowered after 12 months of natalizumab treatment. A 4 fold greater reduction of NfL than of NfHSMI35 suggests differential sensitivity to therapeutic changes using different subunits as the biomarker although NfHSMI35 antibodies detect NfH phosphorylation rather than the protein itself and may reflect different aspects of a given disease. Caution should be taken when MS patient are at risk for other treatment-induced neurological complications that can cause serum NfL levels to rise, such as natalizumab-induced progressive multifocal leukoencephalopathy and ablative hemopoietic stem cell transplantation.

Amyotrophic Lateral Sclerosis

Mutation carriers with ALS symptoms have higher NfPs than those without ALS symptoms (CSF NfL 37-fold, 7388 vs. 195.7 pg/ml), suggesting that elevated NfP levels are linked to disease progression and the symptomatic disease phase. Moreover, elevated serum NfL levels were observed as far back as 1 to 3.5 years before symptom onset depending on different gene mutations (SOD1, 12 months; FUS, 2 years and C9orf72, 3.5 years). CSF NfL levels also correlate with the extent of upper motor neuron and lower motor neuron involvement in ALS. The time to generalization in ALS is an early clinical parameter of disease progression and CSF NfL concentrations have been shown to predict the conversion from bulbar/spinal to generalized ALS. Levels of NfL and pNfH also correlate with survival length in ALS. Higher serum NfL at diagnosis is also one of several factors that predict time of death in ALS. In a recent clinical trial, levels of pNfH and NfL in plasma and CSF were largely unchanged in placebo-treated patients due to superoxide dismutase 1 (SOD1) mutations and decreased in patients treated with tofersen administered intrathecally over a period of 12 weeks, an antisense oligonucleotide that mediates the degradation of SOD1 messenger RNA to reduce SOD1 protein synthesis. Moreover, CSF SOD1 concentration decreased in these tofersen-treated patients with evidence of a slowing in the disease in the total scores on the ALS functional rating scale and the handheld dynamometry megascore.

Alzheimer’s Disease

Plasma NfL is significantly higher in patients with MCI (mild cognitive impairment) (42.8 pg/ml) and patients with AD (51.0 pg/ml) compared with healthy controls (34.7 pg/ml). This finding was further confirmed by other studies. Moreover, higher NfL levels were associated with cognitive decline in non-dementia older adults. Interestingly, elevated plasma NfL is associated with the presence of amyloid-beta plaques in pre-symptomatic individuals whereas NfL levels is associated with the load of tau in symptomatic patients. Plasma NfL is also associated with AD progression independent of amyloid-beta. Plasma NfL levels also correlate with Braak staging and longitudinal increases in plasma NfL are observed in all Braak groupings. In addition, normal plasma NfL level (20.24 pg/ml) is also linked with resistance to PS1 familial AD in apolipoprotein E3 (APOE3) Christchurch mutation. The role of NfL as a potential biomarker for AD has been extensively reviewed and recent meta-analysis regarding its association with AD can be found elsewhere. Recent studies further demonstrated plasma NfL levels or together with cognitive testing as predictors of fast progression and future declines in cognition and function in AD.

Hyperphosphorylation of tau neurofibrillary tangles is one of the hallmarks in AD. CSF ptau181 levels were first found to be increased significantly in patients with AD compared to healthy controls over two decades ago. This finding was subsequently verified by others and later also was confirmed with the measurement of serum ptau181. Recent studies demonstrated that blood ptau181 can predict cortical brain atrophy, tau and amyloid-beta pathology, differentiate AD from other neurodegenerative diseases and identify AD across the clinical continuum. In familial AD, plasma ptau181 levels may rise as early as 16 years before clinical onset. In addition to ptau181, some studies demonstrated ptau217 and ptau231 are also useful biomarkers for AD. The combined use of these AD-specific biomarkers ptau181, ptau217, ptau231 with NfL as a disease-non-specific biomarker of neuronal integrity could improve prediction and monitoring of disease progression in AD.

Frontotemporal Dementia

Serum NfL levels in patients with FTD were about 4-fold higher than in healthy controls (77.9 vs. 19.6 pg/ml) and the elevations correlate with disease severity. Moreover, increased serum NfL levels were observed 1 to 2 years before the clinical onset of symptoms, indicating pathophysiology of the disease in the preclinical phase.

Dementia With Lewy Bodies

Plasma NfL levels in patients with DLB were about 2-fold higher than in healthy controls (55.3 vs. 25.7 pg/ml) and the elevations correlate with disease severity and plasma NfL is the best predictor of cognitive decline compared to age, sex and baseline severity variables over a follow-up of 2 years.

Peripheral Neuropathy

Neurofilament proteins are most abundant in peripheral large-caliber myelinated axons such as sciatic nerves. Plasma NfL levels were about 2-fold higher in patients with inherited peripheral neuropathy CMT than in healthy controls (13.2 vs. 5.2 pg/ml) and correlated with disease severity. Serum NfL was also significantly elevated in acquired peripheral neuropathy and their levels correlated not only with disease severity and outcome but also declined with remission. These studies suggest that NfL might be a promising biomarker for disease activity monitoring of peripheral neuropathy.

Parkinson’s Disease

Plasma NfL levels were about 1.6-fold higher in patients with advanced Hoehn-Yahr stage and patients with PD dementia than in healthy controls (17.6 vs. 10.6 pg/ml) and correlated with disease severity. Higher baseline plasma levels of NfL were also associated with greater motor and cognitive decline after a follow-up period of 3 years in patients with PD, suggesting value of NfL as a predictive biomarker of disease severity and progression in this disease. A recent study also suggests that higher serum NfL levels were also associated with dopamine transporter concentration.

Huntington Disease

Plasma NfL levels were about 3-fold higher in patients with HD than in healthy controls (3.63 vs. 2.68 log pg/ml) and also significantly higher in manifest HD than premanifest HD. Increased CSF and plasma NfL appeared in young adult carriers of HD gene mutation approximately 24 years before the clinical onset of symptoms. Each CAG (cytosine, adenine and guanine trinucleotide repeat) increase is associated with higher, more steeply rising NfL levels.

Stroke

Cerebrospinal fluid NfL was first reported to correlate with outcome after aneurysmal subarachnoid hemorrhage followed by the observations of increased CSF pNfH levels in acute ischemic stroke (8-fold at week 3 after stoke, 2.96 vs. 0.35 ng/ml in controls). The findings were replicated with the measurements of serum NfL levels that patients with recent subcortical infarcts had higher NfL baseline levels compared to healthy controls. Elevated plasma NfL was also associated with poor functional outcome and mortality rate after spontaneous subarachnoid hemorrhage. The elevated NfL levels continued at the 3-month follow-up and seemed to return to normal at 15-month after stroke, indicating that levels of NfL could be a tool for monitoring infarct extent, predicting cognitive function and mortality in patients with stroke. Serum NfL levels also correlate with disease severity, disease progression and 17-year survival in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) caused by mutations in the NOTCH3 gene. In addition to NfL and pNfH, CSF and serum NfM levels were also elevated in patients with stroke.

Traumatic Brain Injury and Spinal Cord Injury

One month after neurosurgical trauma, there was a distinct peak in CSF (6-fold increase, 2460 vs. 409 ng/ml at baseline) and plasma NfL concentration, which peaked at 1-month post-surgery, returning to baseline after 6 to 9 months. Boxers who received severe head impact (>15 hits to the head or experienced grogginess during or after bout) had elevated plasma NfL at 7–10 days after a bout compared to boxers who received mild head impact (<15 head hits). In TBI, both CSF and serum NfL levels were elevated over the first 1–2 weeks compared to healthy controls, decreased over 5 years and correlated with measures of functional outcome. Similar to TBI, CSF and serum NfL concentrations are also increased in SCI patients compared to healthy controls, correlated with motor outcome 3–12 months after trauma and minocycline treatment showed decreased NfL levels in a subgroup of injured patients. Care must be taken when TBI patients are over 60 years old or having pre-existing neurological conditions. In addition to NfL, serum pNfH was also increased in TBI and SCI patients and appears to be a predictive biomarker for outcome.

Spinal Muscular Atrophy

Spinal Muscular Atrophy (MSA) is a rare neuromuscular disorder due to a mutation of survival of motor neuron 1 gene that results in the loss of motor neurons and progressive muscle wasting. Baseline levels of CSF NfL (31-fold, 4598 vs. 148 pg/ml) and tau (2.3-fold, 939 vs. 404 pg/ml) were significantly higher in children with SMA than in controls. Treatment with nusinersen, a drug that increases the level of SMN protein in the CNS normalized NfL and tau levels which correlated with degree of motor improvement in children with SMA. Plasma pNFH levels were also observed to correlate with disease activity and treatment response in infants with MSA treated with nusinersen.

Spinocerebellar Ataxia Type 3

Spinocerebellar ataxia type 3 is a condition characterized by progressive problems with movement due to mutations in the ataxin 3 gene. Plasma NfL levels were about 4-fold higher in patients with SCA3 than in healthy controls (34.8 vs. 8.6 pg/ml) and correlate with disease severity, disease progression and CAG repeat length of ataxin 3 gene mutation. Increased serum NfL appeared in mutation carriers 7.5 years before the clinical onset of symptoms.

Human Immunodeficiency Virus Infection

Human immunodeficiency virus (HIV) invades brain and leads to the CNS injury, most severely manifesting as HIV-associated dementia with high morbidity and mortality. CSF and plasma NfL levels were elevated in HIV infection, especially in HIV-associated dementia (44-fold increase for CSF NfL, 16185 vs. 363 nmol/L in HIV-negative controls), and is markedly reduced after antiretroviral treatment-induced viral suppression. Plasma NfL is also negatively associated with neuropsychological performance in HIV-infected individuals and their levels decline with initiation of antiretroviral therapy.

Prion Diseases

Prion diseases are a family of rare progressive neurodegenerative disorders that affect both humans and animals. CSF and blood NfL levels are significantly higher (about 4-fold increase) in both sporadic and genetic prion disease compared to healthy controls. Increased plasma NfL appeared in adult carriers of prion gene mutation as early as 2 years before the clinical onset of symptoms.

Hereditary Transthyretin-Mediated Amyloidosis

Hereditary transthyretin-mediated amyloidosis is a condition with adult onset caused by mutation of transthyretin and characterized by extracellular deposition of amyloid and destruction of the somatic and autonomic PNS. Plasma NfL levels in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy were 4-fold higher than in healthy controls (69.4 vs. 16.3 pg/ml). Levels of NfL at 18 months increased in placebo-treated patients (99.5 pg/ml) and decreased in patients treated with patisiran (48.8 pg/ml), a gene-silencing drug that interferes with the production of an abnormal form of transthyretin. The levels of 66 proteins in blood were significant changed following patisiran treatment relative to placebo, with change in NfL being the most significant. Moreover, at 18 months, improvement in mNIS + 7 (a robust and clinically meaningful measure of neuropathy progression) compared to baseline in patisiran-treated patients significantly correlated with a reduction of plasma NfL levels.

Late Infantile Neuronal Ceroid Lipofuscinosis Type 2

Ceroid lipofuscinosis type 2 (CLN2) disease is an inherited disorder that primarily affects the nervous system. Before treatment in CLN2 patients, plasma NfL levels were 48-fold higher than in healthy controls (153.2 vs. 3.21 pg/ml) and in CLN2 disease, subjects receiving replacement therapy with cerliponase alfa, plasma NfL levels decreased by 50% each year over 3 years of treatment. Cerliponase alfa-treated patients demonstrated fewer declines in motor and language function than that in historical controls. The fold change of CSF NfL compared with healthy controls has been shown varied extensively between individual conditions, with the smallest effect sizes observed in subjective cognitive decline and PD, and the largest effect sizes observed in cardiac arrest, HIV-associated dementia, FTD/ALS, ALS and HD. The pre-treatment plasma NfL levels observed in CLN2 disease patients is at the high end of neurological disease levels – similar to that seen in ALS, FTD/ALS, HIV-associated dementia and higher than many other neurodegenerative diseases. Even within ALS group, the CSF NfL levels in patients with lower motor neuron signs (346 pg/ml) only had 2.6-fold increase compared with healthy controls (138 pg/ml) while 17.6-fold increase was observed in those with signs of upper motor neuron disease (2435 pg/ml). Therefore, the fold change in CSF and serum NfL levels could be due to damage to different neuronal compartments in different nervous system regions.

Brain Cancer

Neurofilament light chain levels in serum are sensitive to any neuronal damage. As CNS tumors grow bigger and bigger, they could affect function and integrity of neighboring neurons and/or may cause increased intracranial pressure that compromises neuronal function. Accordingly, levels of serum NfL in patients with CNS tumors with progressive disease were 33-fold higher than in healthy controls (239.3 vs. 7.2 pg/ml) and vary closely with tumor activity. Similarly, neurons could be damaged by the infiltration of the brain metastasis in the brain parenchyma, brain compression caused by metastasis, vascular disturbance and toxic products diffusing from tumor cells. In fact, serum NfL levels in patients with metastatic solid tumors with known brain metastasis were 19-fold higher than in healthy controls (142.3 vs. 7.2 pg/ml). This finding was later confirmed and expanded that an increase in serum NfL could be detected 3 months before brain metastasis diagnosis and a high level of NfL at time of brain metastasis correlated with an inferior survival. These studies imply serum NFL is a potential clinical biomarker for both CNS tumors and metastatic solid tumors with brain metastasis.

Cardiac Arrest

Neurons in the brain can be damaged due to prolonged oxygen and sugar deprivation within 3 min of the heart stopping. CSF NfL levels were first reported to be increased in adult patients with cardiac arrest (52-fold, 11,381 vs. 217 pg/ml in healthy controls) and highly predictive of poor outcome. This finding was later confirmed and also with plasma or serum NfL levels. Recently, similar findings were also reported in pediatric patients with cardiac arrest. Cardiac arrest over 3 min can lead to not only hypoxic-ischemic brain damage but also reperfusion injury, the restoration of blood flow after resuscitation placing oxidative stress on the brain as pooled toxins flood already-damaged tissues. Future studies in large dedicated cardiac arrest cohorts with serial longitudinal measurements of serum NfL and parallel analyses to assess changes caused by hypoxia, ischemia and reperfusion in brain are warranted.

Delirium

Serum NfL levels in delirium in hip fracture patients were 1.7-fold higher than in controls (94 vs. 54 pg/ml) and plasma NfL was associated with delirium severity independent of changes in inflammation. In addition to elevated NfL, higher serum pNfH levels also correlated with more severe postoperative delirium. These results suggests NfPs can be sensitive markers of neuronal injury associated with delirium.

The Value of Neurofilament Proteins in Differential Diagnosis Is Limited

Although NfPs are not disease-specific, they may have limited utility in differential diagnosis in some cases. Some neurodegenerative diseases share part of their symptomatology and neuropathology, making it difficult to differentiate between them. The differentiation between multiple system atrophy (MSA) and PD is difficult, particularly in early disease stages. Increased CSF NfL may offer clinically relevant, high accuracy discrimination between MSA and PD and also between PD and other atypical parkinsonian disorders including progressive supranuclear palsy and corticobasal degeneration. The overlap of FTD and ALS has been well documented in FTD patients with co-morbid motor neuron degeneration and in ALS patients with frontotemporal dysfunction. CSF NfL levels are higher in ALS than in FTD and also significantly higher in patients with FTD-ALS than in patients with FTD without ALS. CSF pNfH has also been shown to be a better biomarker than CSF NfL in differentiating ALS from other diseases mimicking ALS symptomatology. Early symptoms of patients with FTD typically do not include memory impairment but instead often manifest changes in their behavior, personality and social interaction, which are often confused with symptoms occurring in psychiatric disorders. About 50% behavioral variant FTD patients received a prior diagnosis of a psychiatric disorder in a large retrospective study. Patients with FTD have significantly higher serum NfL levels than patients with psychiatric disorders, suggesting NfL as a promising tool to help differentially diagnose FTD and psychiatric disorders.

Blood-Brain and Blood-Cerebrospinal Fluid Barriers

The effects of blood-brain barrier (BBB) and blood-CSF barrier (BCB) on serum NfP levels are not fully understood. Aging and neurodegenerative disease can cause increased disruption of the BBB which could contribute to the elevated levels of serum NfP signals observed in these conditions. Recent evidence suggests that serum NfL level does not correlate with opening of the blood brain barrier after cranial irradiation. Consistent with this finding, higher CSF/serum-albumin ratios were observed in FTD-3 patients, but this did not affect the significant associations among serum NfL levels and pre-symptomatic, symptomatic CHMP2B (charged multivesicular body protein 2B) mutation carriers and healthy family controls.

The Exact Form of Extracellular Neurofilament Proteins and Degradation Fragments

Because full length NfL proteins have never been detected in CSF and blood, it seems likely that most or all of the NfL detected in the CSF or serum are peptides generated from partial degradation of NfL in neurons or after their release. The identity and form(s) of NfPs detected by the commonly used NfL antibodies is not fully clarified. Recent studies suggest that a 22 kDa degradation fragment could be the detected plasma signal of NfL since it is also increased in ALS patients. The peptide species of INA and PRPH in CSF and plasma are not known. If a Nf subunit such as INA is fully and rapidly degraded into amino acids upon release from neuronal compartments into blood, then no signals of Simoa assay can be measured and no value of utility as a biomarker. Determination of the form of detected NfP immunosignals (full length or degradation fragments) in blood will not only impact their utility as blood biomarkers but also help to better understanding the pathophysiological process in a given neurological diseases.

The Relationship Among Different Neurofilament Subunits

Neurofilament proteins are not identical and each has a distinct structure and could potentially have differential diagnostic value as biomarkers. The relationships among NfPs are complex and interrelated. When NfL is absent in mice, NfH levels decline most, followed by the decreased levels of NfM and PRPH and the levels of INA is only marginally declined. When NfM is absent in mice, NfL levels decline most, followed by the lowered levels of NfH and INA. NfL and NfM are co-regulated in mammalian brain and only marginally affected by the deletion of NfH, INA or both. The first ELISA for NfPs was developed prior to the recognition of INA and PRPH as additional Nf subunits. NfL is the most intensively studied subunit as a biomarker followed by phosphorylated NfH, especially after introduction of a highly sensitive digital assay.

Despite less attention being paid to NfM, INA and PRPH as biomarkers in neurological diseases, their potential utility is considerable. In addition to the well-established increase of NfL during aging, a highly significant increase in the levels in CSF of both phosphorylated and non-phosphorylated NfM and NfH are also seen in aged individuals as compared with young controls. NfPs are an integral part of neurofibrillary tangles in AD brain and C-terminal phosphorylation sites of both NfM and NfH are 4- to 8-fold more abundant in AD compared with control brain. Levels of specific phosphorylation sites on NfM and NfH in blood could potentially be used as a biomarker to discriminate AD from normal brain aging and other neurological conditions.

Alpha-internexin is enriched in CNS and its prominent aggregation in Nf inclusion disease could qualify INA as a CNS-selective biomarker. However, the intact form of INA is difficult to detect in laboratory practice due to its instability. A possible solution could be to test for blood levels of its more stable degradation products. INA was identified by proteomics as a novel biomarker in the CSF of patients with hemorrhagic stroke. In contrast to INA, PRPH is enriched in PNS and therefore could potentially be developed as a PNS-specific biomarker. Moreover, PRPH is also sensitive to diffuse axonal injury and its aggregate-inducing isoform Per 28 is upregulated in ALS and is associated with disease pathology. A recent report suggests high serum levels of PRPH might be a general biomarker of axon disorders of lower motor neurons. Future studies should therefore aim to develop assays of appropriate specificity for each of the NfP subunits or degradation fragments to explore the complementary information they may contribute to NfP pathobiology and use as biomarkers.

Stable Isotope Labeling Kinetics Coupled With Mass Spectrometry

The levels of NfP and peptide in CSF and blood depend on the rates of synthesis of NfPs or mechanism and rates of NfP peptide release. A recently developed stable isotope labeling method coupled with mass spectrometry may be useful to define the kinetics of NfP turnover in healthy individuals, with aging and in patients with neurological conditions associated with elevated NfP signals in CSF and blood. Special attention should be paid to the extremely slow turnover of NfPs incorporated into the filamentous lattice in axons. This method uses hours-long infusions of 13C and 15N stable isotopes before measuring the labeled proteins in CSF, blood or brain tissue samples. The incorporation of newly synthesized labeled proteins gradually increases until a steady state is reached. Following stop of infusions, the proportion of the labeled amino acid in the target protein gradually declines as a result of protein clearance or degradation. Alterations in the isotopic enrichment of the target proteins allow the calculation of protein synthesis and clearance rates from the ratio of labeled to non-labeled protein. This method was used to measure the kinetics of tau isoforms and fragments in human CNS. The elevated CNS tau levels in AD patients was initially interpreted as resulting from passive release of this protein by degenerative neurons. However, results from stable isotope labeling kinetics (SILK) studies suggest that the bulk of tau in human CSF is released by an active process that is stimulated by neuronal exposure to aggregated amyloid-beta. On the one hand, the concentration of NfPs in CSF or serum measured at a given time represents a static biomarker whose equilibrium could be affected by various factors. On the other hand, NfP-SILK can provide dynamic measure of production and clearance of newly synthesized NfPs that might provide a more detailed understanding of the mechanisms underlying these alterations in NfP levels.

Confounding Factors

Since there are significant variations of measured blood NfL levels among different methods and labs, standardization of blood NfL measurement globally is needed. Care must be taken when interpreting results obtained in different studies. Community-based large populations of healthy individuals are required to generate normative data for reference intervals. As discussed earlier, there are numerous demographic, life style, and comorbidity factors that potentially influence NfP levels in biological samples. With the increasing use of blood assays, variables such as exercise, blood volume, body mass index need to be considered. Trace amounts of NfPs relative to those in neurons have been reported in erythrocytes, T lymphocytes, podocytes, and oocytes, which could be confounds in certain disease conditions. Because blood NfL alteration is associated with aging, future studies are also needed to establish the age-adjusted normal values of serum NfL levels across all age groups. The recent establishment of reference intervals of serum NfL in 342 Scandinavian reference subjects from 18 to 87 years of age is a step in the right direction. Comparative studies of two or more neurological disorders will be valuable to clarify the relative magnitude of change and its disease significance using the same methodologies. Sporadic AD patients are often older individuals associated with higher prevalence of cardiovascular conditions that is also associated with CNS ischemic damage and subsequent release of NfPs into blood. Co-existing peripheral neuropathy with CNS diseases may also weaken the correlation between CSF and serum NfP signals. Longitudinal measurements should also be encouraged to minimize intra- and inter-individual variation due to transient confounding variables and emerging co-morbidities.

Conclusion

The development of minimally invasive ultrasensitive assays of NfPs released from neurons into in blood has increased the potential use of NfPs as biomarkers especially for repeated measurements during longitudinal studies such as in MS. The degree of elevation of NfPs in serum could easily differentiate behavioral FTD from primary psychiatric disorders where significant clinical overlaps of these two conditions exist and the sensitivity and specificity of structural and functional imaging methods remain imperfect. Monitoring the kinetics of NfPs in blood can increase our ability to assess disease activity, neuronal injury, and neurodegeneration in real time and to measure treatment effectiveness. Much interest has been focused on the detection of blood NfPs by high-sensitivity assays as a surrogate marker of neuronal structural damage and degeneration. However, the majority of these reports are cross-sectional, more longitudinal data are required to better elucidate the place of NfPs in the clinical settings. Due to their lack of specificity for a given disease, NfPs will most likely be of limited value as a diagnostic tool except when levels drastically differ between two conditions with similar clinical presentations. No single test or value of NfPs can currently be used to rule in or exclude the diagnosis of a specific disease. Nevertheless, NfPs can potentially be used to monitor disease progression and the effects of therapeutic intervention in combination with clinical judgment in almost any neuronal injury and neurological diseases. Serum NfPs are relatively easily measured. Treatment-induced decrease in blood NfPs levels as a complement to the more lengthy process of measuring clinical outcomes may, in the future, be more important in the validation and regulatory approval of new drugs for neurological conditions.

Author Contributions

AY and RN wrote the manuscript and have approved it for publication. Both authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 367

  1. 1.

    Abdulle S. Mellgren A. Brew B. J. Cinque P. Hagberg L. Price R. W. (2007 ). CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. J. Neurol. 254 1026–1032.

    Not in our library10.1007/s00415-006-0481-8

  2. 2.

    Adiutori R. Aarum J. Zubiri I. Bremang M. Jung S. Sheer D. (2018 ). The proteome of neurofilament-containing protein aggregates in blood. Biochem. Biophys. Rep. 14 168–177.

    Not in our library10.1016/j.bbrep.2018.04.010

  3. 3.

    Akgun K. Kretschmann N. Haase R. Proschmann U. Kitzler H. H. Reichmann H. (2019 ). Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol. Neuroimmunol. Neuroinflamm. 6:e555.

    Not in our library10.1212/nxi.0000000000000555

  4. 4.
    Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light · 2015
    No notice
  5. 5.

    Al Shweiki M. R. Steinacker P. Oeckl P. Hengerer B. Danek A. Fassbender K. (2019 ). Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J. Psychiatr. Res. 113 137–140.

    Not in our library10.1016/j.jpsychires.2019.03.019

  6. 6.

    Alagaratnam J. Von Widekind S. De Francesco D. Underwood J. Edison P. Winston A. (2021 ). Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurol. Open 3:e000143.

    Not in our library10.1136/bmjno-2021-000143

  7. 7.

    Alami N. H. Smith R. B. Carrasco M. A. Williams L. A. Winborn C. S. Han S. S. W. (2014 ). Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81 536–543.

    Not in our library10.1016/j.neuron.2013.12.018

  8. 8.
    Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways · 2018
    No notice
  9. 9.

    Altick A. L. Baryshnikova L. M. Vu T. Q. Von Bartheld C. S. (2009 ). Quantitative analysis of multivesicular bodies (MVBs) in the hypoglossal nerve: evidence that neurotrophic factors do not use MVBs for retrograde axonal transport. J. Comp. Neurol. 514 641–657.

    Not in our library10.1002/cne.22047

  10. 10.

    Anderson A. M. Easley K. A. Kasher N. Franklin D. Heaton R. K. Zetterberg H. (2018 ). Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J. Neurovirol. 24 695–701.

    Not in our library10.1007/s13365-018-0664-y

  11. 11.

    Arboleda-Velasquez J. F. Lopera F. O’hare M. Delgado-Tirado S. Marino C. Chmielewska N. (2019 ). Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25 1680–1683.

    Not in our library10.1038/s41591-019-0611-3

  12. 12.

    Arun P. Rossetti F. Eken O. Wilder D. Wang Y. Long J. (2021 ). Phosphorylated neurofilament heavy chain in the cerebrospinal fluid is a suitable biomarker of acute and chronic blast-induced traumatic brain injury. J. Neurotrauma. [Preprint].

    Not in our library10.1089/neu.2021.0144

  13. 13.
    A multicentre validation study of the diagnostic value of plasma neurofilament light · 2021
    No notice
  14. 14.
    Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration · 2019
    No notice
  15. 15.
    Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology · 2021
    No notice
  16. 16.

    Aspelund A. Antila S. Proulx S. T. Karlsen T. V. Karaman S. Detmar M. (2015 ). A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212 991–999.

    Not in our library10.1084/jem.20142290

  17. 17.

    Bacioglu M. Maia L. F. Preische O. Schelle J. Apel A. Kaeser S. A. (2016 ). Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91 494–496.

    Not in our library10.1016/j.neuron.2016.07.007

  18. 18.
    NfL as a biomarker for neurodegeneration and survival in Parkinson disease · 2020
    No notice
  19. 19.

    Barro C. Benkert P. Disanto G. Tsagkas C. Amann M. Naegelin Y. (2018 ). Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141 2382–2391.

    Not in our library10.1093/brain/awy154

  20. 20.

    Bateman R. J. Munsell L. Y. Morris J. C. Swarm R. Yarasheski K. E. Holtzman D. M. (2006 ). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12 856–861.

    Not in our library10.1038/nm1438

  21. 21.

    Beaulieu J. M. Nguyen M. D. Julien J. P. (1999 ). Late onset of motor neurons in mice overexpressing wild-type peripherin. J. Cell Biol. 147 531–544.

    Not in our library10.1083/jcb.147.3.531

  22. 22.

    Benatar M. Wuu J. Andersen P. M. Lombardi V. Malaspina A. (2018 ). Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84 130–139.

    Not in our library10.1002/ana.25276

  23. 23.

    Benatar M. Wuu J. Lombardi V. Jeromin A. Bowser R. Andersen P. M. (2019 ). Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Frontotemporal Degener. 20 538–548.

    Not in our library10.1080/21678421.2019.1646769

  24. 24.

    Benedet A. L. Leuzy A. Pascoal T. A. Ashton N. J. Mathotaarachchi S. Savard M. (2020 ). Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease. Brain 143 3793–3804.

    Not in our library10.1093/brain/awaa342

  25. 25.

    Benedict C. Blennow K. Zetterberg H. Cedernaes J. (2020 ). Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. Neurology 94 e1181–e1189.

    Not in our library10.1212/wnl.0000000000008866

  26. 26.

    Bergman J. Dring A. Zetterberg H. Blennow K. Norgren N. Gilthorpe J. (2016 ). Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol. Neuroimmunol. Neuroinflamm. 3:e271.

    Not in our library10.1212/nxi.0000000000000271

  27. 27.

    Bischof A. Manigold T. Barro C. Heijnen I. Berger C. T. Derfuss T. (2018 ). Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann. Rheum. Dis. 77 1093–1094.

    Not in our library10.1136/annrheumdis-2017-212045

  28. 28.

    Bjornevik K. Munger K. L. Cortese M. Barro C. Healy B. C. Niebuhr D. W. (2019 ). Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 77 58–64.

    Not in our library10.1001/jamaneurol.2019.3238

  29. 29.

    Bomont P. Cavalier L. Blondeau F. Ben Hamida C. Belal S. Tazir M. (2000 ). The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat. Genet. 26 370–374.

    Not in our library10.1038/81701

  30. 30.

    Bos I. Vos S. Verhey F. Scheltens P. Teunissen C. Engelborghs S. (2019 ). Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimers Dement. 15 644–654.

    Not in our library10.1016/j.jalz.2019.01.004

  31. 31.

    Boylan K. Yang C. Crook J. Overstreet K. Heckman M. Wang Y. (2009 ). Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J. Neurochem. 111 1182–1191.

    Not in our library10.1111/j.1471-4159.2009.06386.x

  32. 32.

    Brettschneider J. Petzold A. Sussmuth S. D. Ludolph A. C. Tumani H. (2006 ). Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66 852–856.

    Not in our library10.1212/01.wnl.0000203120.85850.54

  33. 33.

    Bridel C. Van Wieringen W. N. Zetterberg H. Tijms B. M. Teunissen C. E. (2019 ). Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 76 1035–1048.

    Not in our library10.1001/jamaneurol.2019.1534

  34. 34.

    Brownlees J. Ackerley S. Grierson A. J. Jacobsen N. J. Shea K. Anderton B. H. (2002 ). Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum. Mol. Genet. 11 2837–2844.

    Not in our library10.1093/hmg/11.23.2837

  35. 35.

    Brureau A. Blanchard-Bregeon V. Pech C. Hamon S. Chaillou P. Guillemot J. C. (2017 ). NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol. Dis. 104 73–84.

    Not in our library10.1016/j.nbd.2017.04.007

  36. 36.

    Byg K. E. Nielsen H. H. Sejbaek T. Madsen J. S. Olsen D. A. Nguyen N. (2021 ). Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis. Brain Sci. 11:238.

    Not in our library10.3390/brainsci11020238

  37. 37.
    Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis · 2017
    No notice
  38. 38.

    Byrne L. M. Rodrigues F. B. Johnson E. B. Wijeratne P. A. De Vita E. Alexander D. C. (2018 ). Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. Sci. Transl. Med. 10:eaat7108.

    Not in our library10.1126/scitranslmed.aat7108

  39. 39.

    Cairns N. J. Zhukareva V. Uryu K. Zhang B. Bigio E. Mackenzie I. R. (2004 ). alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am. J. Pathol. 164 2153–2161.

    Not in our library10.1016/s0002-9440(10)63773-x

  40. 40.

    Calabresi P. A. Arnold D. L. Sangurdekar D. Singh C. M. Altincatal A. De Moor C. (2020 ). Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Mult. Scler. 2020:1352458520972573.

    Not in our library10.1177/1352458520972573

  41. 41.

    Carare R. O. Bernardes-Silva M. Newman T. A. Page A. M. Nicoll J. A. Perry V. H. (2008 ). Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 34 131–144.

    Not in our library10.1111/j.1365-2990.2007.00926.x

  42. 42.

    Carmona-Iragui M. Alcolea D. Barroeta I. Videla L. Munoz L. Van Pelt K. (2021 ). Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurol. 20 605–614.

    Not in our library10.1016/s1474-4422(21)00129-0

  43. 43.

    Casey C. P. Lindroth H. Mohanty R. Farahbakhsh Z. Ballweg T. Twadell S. (2019 ). Postoperative delirium is associated with increased plasma neurofilament light. Brain 143 47–54.

    Not in our library10.1093/brain/awz354

  44. 44.

    Ching G. Y. Chien C. L. Flores R. Liem R. K. (1999 ). Overexpression of alpha-internexin causes abnormal neurofilamentous accumulations and motor coordination deficits in transgenic mice. J. Neurosci. 19 2974–2986.

    Not in our library10.1523/jneurosci.19-08-02974.1999

  45. 45.

    Clark C. Lewczuk P. Kornhuber J. Richiardi J. Marechal B. Karikari T. K. (2021 ). Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression. Alzheimers Res. Ther. 13:65.

    Not in our library10.1186/s13195-021-00805-8

  46. 46.

    Clay A. Obrochta K. M. Soon R. K. Jr. Russell C. B. Lynch D. R. (2020 ). Neurofilament light chain as a potential biomarker of disease status in Friedreich ataxia. J. Neurol. 267 2594–2598.

    Not in our library10.1007/s00415-020-09868-3

  47. 47.

    Cleveland D. W. Rothstein J. D. (2001 ). From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2 806–819.

    Not in our library10.1038/35097565

  48. 48.
    Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia · 2021
    Not checked
  49. 49.

    Constantinescu R. Rosengren L. Johnels B. Zetterberg H. Holmberg B. (2010 ). Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat. Disord. 16 142–145.

    Not in our library10.1016/j.parkreldis.2009.07.007

  50. 50.

    Cote F. Collard J. F. Julien J. P. (1993 ). Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73 35–46.

    Not in our library10.1016/0092-8674(93)90158-m

  51. 51.

    Cuello J. P. Martinez Gines M. L. Kuhle J. Garcia Dominguez J. M. Lozano Ros A. Romero Delgado F. (2019 ). Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. Eur. J. Neurol. 26 1200–1204.

    Not in our library10.1111/ene.13965

  52. 52.

    Dalla Costa G. Martinelli V. Moiola L. Sangalli F. Colombo B. Finardi A. (2019 ). Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann. Neurol. 85 606–610.

    Not in our library10.1002/ana.25437

  53. 53.

    Damasceno A. Dias-Carneiro R. P. C. Moraes A. S. Boldrini V. O. Quintiliano R. P. S. Da Silva V. (2019 ). Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS. Mult. Scler. Relat. Disord. 30 149–153.

    Not in our library10.1016/j.msard.2019.02.004

  54. 54.

    Dang Do A. N. Sinaii N. Masvekar R. R. Baker E. H. Thurm A. E. (2020 ). Neurofilament light chain levels correlate with clinical measures in CLN3 disease. Genet. Med. 23 751–757.

    Not in our library10.1038/s41436-020-01035-3

  55. 55.

    Darras B. T. Crawford T. O. Finkel R. S. Mercuri E. De Vivo D. C. Oskoui M. (2019 ). Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6 932–944.

    Not in our library10.1002/acn3.779

  56. 56.

    De Jong D. Jansen R. W. Pijnenburg Y. A. Van Geel W. J. Borm G. F. Kremer H. P. (2007 ). CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78 936–938.

    Not in our library10.1136/jnnp.2006.107326

  57. 57.

    De Leon M. J. Li Y. Okamura N. Tsui W. H. Saint-Louis L. A. Glodzik L. (2017 ). Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. J. Nucl. Med. 58 1471–1476.

    Not in our library10.2967/jnumed.116.187211

  58. 58.

    Delaby C. Alcolea D. Carmona-Iragui M. Illan-Gala I. Morenas-Rodriguez E. Barroeta I. (2020 ). Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci. Rep. 10:9161.

    Not in our library10.1038/s41598-020-66090-x

  59. 59.
    Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury · 2018
    Not checked
  60. 60.

    Disanto G. Adiutori R. Dobson R. Martinelli V. Dalla Costa G. Runia T. (2016 ). Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J. Neurol. Neurosurg. Psychiatry 87 126–129.

    Not in our library10.1136/jnnp-2014-309690

  61. 61.

    Disanto G. Barro C. Benkert P. Naegelin Y. Schadelin S. Giardiello A. (2017 ). Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81 857–870.

    Not in our library10.1002/ana.24954

  62. 62.

    Disanto G. Prosperetti C. Gobbi C. Barro C. Michalak Z. Cassina T. (2019 ). Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. Epilepsy Behav. 101 106432.

    Not in our library10.1016/j.yebeh.2019.07.033

  63. 63.

    Douglas-Escobar M. Yang C. Bennett J. Shuster J. Theriaque D. Leibovici A. (2010 ). A pilot study of novel biomarkers in neonates with hypoxic-ischemic encephalopathy. Pediatr. Res. 68 531–536.

    Not in our library10.1203/pdr.0b013e3181f85a03

  64. 64.

    Edwards L. A. Donnelly C. G. Reed S. M. Valberg S. Chigerwe M. Johnson A. L. (2021 ). Serum and cerebrospinal fluid phosphorylated neurofilament heavy protein concentrations in equine neurodegenerative diseases. Equine Vet. J.

    Not in our library10.1111/evj.13452

  65. 65.

    Egle M. Loubiere L. Maceski A. Kuhle J. Peters N. Markus H. S. (2021 ). Neurofilament light chain predicts future dementia risk in cerebral small vessel disease. J. Neurol. Neurosurg. Psychiatry. 92 582–589.

    Not in our library10.1136/jnnp-2020-325681

  66. 66.

    Ehler J. Petzold A. Wittstock M. Kolbaske S. Gloger M. Henschel J. (2019 ). The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study. PLoS One 14:e0211184.

    Not in our library10.1371/journal.pone.0211184

  67. 67.

    Elder G. A. Friedrich V. L. Jr. Margita A. Lazzarini R. A. (1999 ). Age-related atrophy of motor axons in mice deficient in the mid-sized neurofilament subunit. J. Cell Biol. 146 181–192.

    Not in our library10.1083/jcb.146.1.181

  68. 68.

    Engelhardt B. Vajkoczy P. Weller R. O. (2017 ). The movers and shapers in immune privilege of the CNS. Nat. Immunol. 18 123–131.

    Not in our library10.1038/ni.3666

  69. 69.

    Evered L. Silbert B. Scott D. A. Zetterberg H. Blennow K. (2018 ). Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery: Results From the CAPACITY and ARCADIAN Studies. JAMA Neurol. 75 542–547.

    Not in our library10.1001/jamaneurol.2017.4913

  70. 70.

    Evers K. S. Atkinson A. Barro C. Fisch U. Pfister M. Huhn E. A. (2018 ). Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. Hypertension 71 1178–1184.

    Not in our library10.1161/hypertensionaha.117.10314

  71. 71.

    Evers K. S. Hugli M. Fouzas S. Kasser S. Pohl C. Stoecklin B. (2020 ). Serum Neurofilament Levels in Children With Febrile Seizures and in Controls. Front. Neurosci. 14:579958.

    Not in our library10.3389/fnins.2020.579958

  72. 72.

    Fagan A. M. Shaw L. M. Xiong C. Vanderstichele H. Mintun M. A. Trojanowski J. Q. (2011 ). Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch. Neurol. 68 1137–1144.

    Not in our library10.1001/archneurol.2011.105

  73. 73.

    Filali M. Dequen F. Lalonde R. Julien J. P. (2011 ). Sensorimotor and cognitive function of a NEFL(P22S) mutant model of Charcot-Marie-Tooth disease type 2E. Behav. Brain Res. 219 175–180.

    Not in our library10.1016/j.bbr.2010.12.022

  74. 74.

    Filippi P. Vestenicka V. Siarnik P. Sivakova M. Copikova-Cudrakova D. Belan V. (2020 ). Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis. Neuro Endocrinol. Lett. 41 17–26.

    Not in our library

  75. 75.

    Finderlater J. (2010 ). Peripherin-28 as a biomarker of ALS: A methodological study. Toronto: University of Toronto.

    Not in our library

  76. 76.

    Fischer A. Sananbenesi F. Pang P. T. Lu B. Tsai L. H. (2005 ). Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48 825–838.

    Not in our library10.1016/j.neuron.2005.10.033

  77. 77.

    Foiani M. S. Woollacott I. O. Heller C. Bocchetta M. Heslegrave A. Dick K. M. (2018 ). Plasma tau is increased in frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 89 804–807.

    Not in our library10.1136/jnnp-2017-317260

  78. 78.

    Fominykh V. Brylev L. Gaskin V. Luzin R. Yakovlev A. Komoltsev I. (2019 ). Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis. Metab. Brain Dis. 34 1473–1485.

    Not in our library10.1007/s11011-019-00452-x

  79. 79.

    Fong T. G. Vasunilashorn S. M. Ngo L. Libermann T. A. Dillon S. T. Schmitt E. M. (2020 ). Association of Plasma Neurofilament Light with Postoperative Delirium. Ann. Neurol. 88 984–994.

    Not in our library10.1002/ana.25889

  80. 80.

    Fortea J. Carmona-Iragui M. Benejam B. Fernandez S. Videla L. Barroeta I. (2018 ). Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 17 860–869.

    Not in our library10.1016/s1474-4422(18)30285-0

  81. 81.
    A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation · 2018
    No notice
  82. 82.

    Gama Sosa M. A. Friedrich V. L. Jr. Degasperi R. Kelley K. Wen P. H. Senturk E. (2003 ). Human midsized neurofilament subunit induces motor neuron disease in transgenic mice. Exp. Neurol. 184 408–419.

    Not in our library10.1016/s0014-4886(03)00206-1

  83. 83.

    Garland P. Morton M. Zolnourian A. Durnford A. Gaastra B. Toombs J. (2021 ). Neurofilament light predicts neurological outcome after subarachnoid haemorrhage. Brain. [Preprint].

    Not in our library10.1093/brain/awaa451

  84. 84.

    Gattringer T. Pinter D. Enzinger C. Seifert-Held T. Kneihsl M. Fandler S. (2017 ). Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 89 2108–2114.

    Not in our library10.1212/wnl.0000000000004645

  85. 85.
    Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis · 2021
    Not checked
  86. 86.

    Gendron T. F. Badi M. K. Heckman M. G. Jansen-West K. R. Vilanilam G. K. Johnson P. W. (2020 ). Plasma neurofilament light predicts mortality in patients with stroke. Sci. Transl. Med. 12:eaay1913.

    Not in our library10.1126/scitranslmed.aay1913

  87. 87.

    Gille B. De Schaepdryver M. Goossens J. Dedeene L. De Vocht J. Oldoni E. (2019 ). Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol. Appl. Neurobiol. 45 291–304.

    Not in our library10.1111/nan.12511

  88. 88.

    Gisslen M. Price R. W. Andreasson U. Norgren N. Nilsson S. Hagberg L. (2016 ). Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMed. 3 135–140.

    Not in our library10.1016/j.ebiom.2015.11.036

  89. 89.

    Goeral K. Hauck A. Atkinson A. Wagner M. B. Pimpel B. Fuiko R. (2021 ). Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. J. Neurol. 268 2570–2577.

    Not in our library10.1007/s00415-021-10429-5

  90. 90.

    Goldman J. E. Yen S. H. Chiu F. C. Peress N. S. (1983 ). Lewy bodies of Parkinson’s disease contain neurofilament antigens. Science 221 1082–1084.

    Not in our library10.1126/science.6308771

  91. 91.

    Goldstein M. E. Sternberger N. H. Sternberger L. A. (1987 ). Phosphorylation protects neurofilaments against proteolysis. J. Neuroimmunol. 14 149–160.

    Not in our library10.1016/0165-5728(87)90049-x

  92. 92.

    Granger B. L. Lazarides E. (1983 ). Expression of the major neurofilament subunit in chicken erythrocytes. Science 221 553–556.

    Not in our library10.1126/science.6346488

  93. 93.

    Gravesteijn G. Rutten J. W. Verberk I. M. W. Bohringer S. Liem M. K. Van Der Grond J. (2019 ). Serum Neurofilament light correlates with CADASIL disease severity and survival. Ann. Clin. Transl. Neurol. 6 46–56.

    Not in our library10.1002/acn3.678

  94. 94.

    Gronhoj M. H. Sejbaek T. Hansen R. W. Larsen L. Dahl M. Schierbeck J. (2021 ). Serum levels of neurofilament light chain, neuron-specific enolase and S100 calcium-binding protein B during acute bacterial meningitis: a prospective cohort study. Infect. Dis. 2021 1–11.

    Not in our library10.1080/23744235.2021.1883730

  95. 95.

    Grothe M. J. Moscoso A. Ashton N. J. Karikari T. K. Lantero-Rodriguez J. Snellman A. (2021 ). Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology. [Preprint].

    Not in our library10.1212/wnl.0000000000012513

  96. 96.

    Guedes V. A. Kenney K. Shahim P. Qu B. X. Lai C. Devoto C. (2020 ). Exosomal neurofilament light: A prognostic biomarker for remote symptoms after mild traumatic brain injury? Neurology 94 e2412–e2423.

    Not in our library10.1212/wnl.0000000000009577

  97. 97.

    Guez M. Hildingsson C. Rosengren L. Karlsson K. Toolanen G. (2003 ). Nervous tissue damage markers in cerebrospinal fluid after cervical spine injuries and whiplash trauma. J. Neurotrauma 20 853–858.

    Not in our library10.1089/089771503322385782

  98. 98.

    Haggmark A. Mikus M. Mohsenchian A. Hong M. G. Forsstrom B. Gajewska B. (2014 ). Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 1 544–553.

    Not in our library10.1002/acn3.83

  99. 99.

    Halaas N. B. Blennow K. Idland A. V. Wyller T. B. Raeder J. Frihagen F. (2018 ). Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. Dement. Geriatr. Cogn. Disord. 46 346–357.

    Not in our library10.1159/000494754

  100. 100.

    Hamberger A. Huang Y. L. Zhu H. Bao F. Ding M. Blennow K. (2003 ). Redistribution of neurofilaments and accumulation of beta-amyloid protein after brain injury by rotational acceleration of the head. J. Neurotrauma 20 169–178.

    Not in our library10.1089/08977150360547080

  101. 101.
    Blood-based NfL · 2017
    No notice
  102. 102.

    Harris S. Comi G. Cree B. A. C. Arnold D. L. Steinman L. Sheffield J. K. (2021 ). Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of phase 3 ozanimod trials. Eur. J. Neurol. [Preprint].

    Not in our library10.1111/ene.15009

  103. 103.

    Hayakawa K. Okazaki R. Ishii K. Ueno T. Izawa N. Tanaka Y. (2012 ). Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study. Spinal Cord 50 493–496.

    Not in our library10.1038/sc.2011.184

  104. 104.

    Hayashi T. Nukui T. Piao J. L. Sugimoto T. Anada R. Matsuda N. (2021 ). Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Behav. 2021:e02084.

    Not in our library10.1002/brb3.2084

  105. 105.
    Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults · 2020
    Not checked
  106. 106.

    He W. C. Zhang X. J. Zhang Y. Q. Zhang W. J. (2020 ). Elevated serum neurofilament light chain in children autism spectrum disorder: a case control study. Neurotoxicology 80 87–92.

    Not in our library10.1016/j.neuro.2020.06.012

  107. 107.

    Heo S. Diering G. H. Na C. H. Nirujogi R. S. Bachman J. L. Pandey A. (2018 ). Identification of long-lived synaptic proteins by proteomic analysis of synaptosome protein turnover. Proc. Natl. Acad. Sci. U S A. 115 E3827–E3836.

    Not in our library10.1073/pnas.1720956115

  108. 108.

    Hepner A. Porter J. Hare F. Nasir S. S. Zetterberg H. Blennow K. (2019 ). Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas. World J. Oncol. 10 169–175.

    Not in our library10.14740/wjon1228

  109. 109.

    Herbert M. K. Aerts M. B. Beenes M. Norgren N. Esselink R. A. Bloem B. R. (2015 ). CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front. Neurol. 6:91.

    Not in our library10.3389/fneur.2015.00091

  110. 110.

    Herrera M. I. Kolliker-Frers R. A. Otero-Losada M. Perez Lloret S. Filippo M. Tau J. (2019 ). A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis. Front. Neurol. 10:1046.

    Not in our library10.3389/fneur.2019.01046

  111. 111.

    Hoffman P. N. Cleveland D. W. Griffin J. W. Landes P. W. Cowan N. J. Price D. L. (1987 ). Neurofilament gene expression: a major determinant of axonal caliber. Proc. Natl. Acad. Sci. U S A. 84 3472–3476.

    Not in our library10.1073/pnas.84.10.3472

  112. 112.

    Hoglund K. Bogstedt A. Fabre S. Aziz A. Annas P. Basun H. (2012 ). Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer’s disease. J. Alzheimers. Dis. 32 939–947.

    Not in our library10.3233/jad-2012-120976

  113. 113.

    Hossain I. Mohammadian M. Takala R. S. K. Tenovuo O. Lagerstedt L. Ala-Seppala H. (2019 ). Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. J. Neurotrauma 36 1551–1560.

    Not in our library10.1089/neu.2018.5952

  114. 114.

    Hu Y. Y. He S. S. Wang X. C. Duan Q. H. Khatoon S. Iqbal K. (2002 ). Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320 156–160.

    Not in our library10.1016/s0304-3940(02)00047-2

  115. 115.

    Hviid C. V. B. Gyldenholm T. Lauridsen S. V. Hjort N. Hvas A. M. Parkner T. (2020a ). Plasma neurofilament light chain is associated with mortality after spontaneous intracerebral hemorrhage. Clin. Chem. Lab. Med. 58 261–267.

    Not in our library10.1515/cclm-2019-0532

  116. 116.

    Hviid C. V. B. Knudsen C. S. Parkner T. (2020b ). Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand. J. Clin. Lab. Invest. 2020 1–5.

    Not in our library10.1080/00365513.2020.1730434

  117. 117.

    Idland A. V. Sala-Llonch R. Borza T. Watne L. O. Wyller T. B. Braekhus A. (2017 ). CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol. Aging 49 138–144.

    Not in our library10.1016/j.neurobiolaging.2016.09.012

  118. 118.

    Ikenberg E. Reilich P. Abicht A. Heller C. Schoser B. Walter M. C. (2019 ). Charcot-Marie-Tooth disease type 2CC due to a frameshift mutation of the neurofilament heavy polypeptide gene in an Austrian family. Neuromuscul. Disord. 29 392–397.

    Not in our library10.1016/j.nmd.2019.02.007

  119. 119.

    Inoue R. Sumitani M. Ogata T. Chikuda H. Matsubara T. Kato S. (2017 ). Direct evidence of central nervous system axonal damage in patients with postoperative delirium: A preliminary study of pNF-H as a promising serum biomarker. Neurosci. Lett. 653 39–44.

    Not in our library10.1016/j.neulet.2017.05.023

  120. 120.

    Iverson G. L. Reddi P. J. Posti J. P. Kotilainen A. K. Tenovuo O. Ohman J. (2019 ). Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. J. Neurotrauma 36 2400–2406.

    Not in our library10.1089/neu.2018.6341

  121. 121.

    Jakimovski D. Kuhle J. Ramanathan M. Barro C. Tomic D. Hagemeier J. (2019a ). Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann. Clin. Transl. Neurol. 6 1757–1770.

    Not in our library10.1002/acn3.50872

  122. 122.

    Jakimovski D. Zivadinov R. Ramanthan M. Hagemeier J. Weinstock-Guttman B. Tomic D. (2019b ). Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Mult. Scler. 2019:1352458519881428.

    Not in our library10.1177/1352458519881428

  123. 123.

    Jakobsson J. Bjerke M. Ekman C. J. Sellgren C. Johansson A. G. Zetterberg H. (2014 ). Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology 39 2349–2356.

    Not in our library10.1038/npp.2014.81

  124. 124.

    Janelidze S. Mattsson N. Palmqvist S. Smith R. Beach T. G. Serrano G. E. (2020a ). Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med. 26 379–386.

    Not in our library10.1038/s41591-020-0755-1

  125. 125.
    Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease · 2020
    No notice
  126. 126.

    Jeppsson A. Zetterberg H. Blennow K. Wikkelso C. (2013 ). Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurol. 80 1385–1392.

    Not in our library10.1212/wnl.0b013e31828c2fda

  127. 127.
    Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients · 2014
    No notice
  128. 128.

    Jin M. Cao L. Dai Y. P. (2019 ). Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer’s Disease: A Correlative Meta-Analysis. Front. Aging Neurosci. 11:254.

    Not in our library10.3389/fnagi.2019.00254

  129. 129.

    Johnson E. B. Byrne L. M. Gregory S. Rodrigues F. B. Blennow K. Durr A. (2018 ). Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology 90 e717–e723.

    Not in our library10.1212/wnl.0000000000005005

  130. 130.

    Joisten N. Rademacher A. Warnke C. Proschinger S. Schenk A. Walzik D. (2021 ). Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 8:e982.

    Not in our library10.1212/nxi.0000000000000982

  131. 131.

    Kalm M. Bostrom M. Sandelius A. Eriksson Y. Ek C. J. Blennow K. (2017 ). Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Res. 1668 12–19.

    Not in our library10.1016/j.brainres.2017.05.011

  132. 132.

    Kanata E. Golanska E. Villar-Pique A. Karsanidou A. Dafou D. Xanthopoulos K. (2019 ). Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. J. Clin. Neurosci. 60 124–127.

    Not in our library10.1016/j.jocn.2018.09.031

  133. 133.

    Kang M. S. Aliaga A. A. Shin M. Mathotaarachchi S. Benedet A. L. Pascoal T. A. (2020 ). Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease. Mol. Psychiatry. [Preprint].

    Not in our library10.1038/s41380-020-0818-1

  134. 134.

    Kapoor M. Foiani M. Heslegrave A. Zetterberg H. Lunn M. P. Malaspina A. (2019 ). Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J. Peripher. Nerv. Syst. 24 314–319.

    Not in our library10.1111/jns.12350

  135. 135.

    Karikari T. K. Benedet A. L. Ashton N. J. Lantero Rodriguez J. Snellman A. Suarez-Calvet M. (2021 ). Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol. Psychiatry 26 429–442.

    Not in our library10.1038/s41380-020-00923-z

  136. 136.

    Karikari T. K. Emersic A. Vrillon A. Lantero-Rodriguez J. Ashton N. J. Kramberger M. G. (2020a ). Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer’s disease diagnosis. Alzheimers Dement. 17 755–767.

    Not in our library10.1002/alz.12236

  137. 137.

    Karikari T. K. Pascoal T. A. Ashton N. J. Janelidze S. Benedet A. L. Rodriguez J. L. (2020b ). Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19 422–433.

    Not in our library10.1016/s1474-4422(20)30071-5

  138. 138.

    Katisko K. Cajanus A. Jaaskelainen O. Kontkanen A. Hartikainen P. Korhonen V. E. (2020 ). Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J. Neurol. 267 162–167.

    Not in our library10.1007/s00415-019-09567-8

  139. 139.

    Kern S. Syrjanen J. A. Blennow K. Zetterberg H. Skoog I. Waern M. (2019 ). Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurol. 76 187–193.

    Not in our library10.1001/jamaneurol.2018.3459

  140. 140.
    Serum neurofilament light levels in normal aging and their association with morphologic brain changes · 2020
    No notice
  141. 141.

    Khalil M. Teunissen C. E. Otto M. Piehl F. Sormani M. P. Gattringer T. (2018 ). Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14 577–589.

    Not in our library10.1038/s41582-018-0058-z

  142. 142.

    Kida S. Pantazis A. Weller R. O. (1993 ). CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 19 480–488.

    Not in our library10.1111/j.1365-2990.1993.tb00476.x

  143. 143.

    Kirschen M. P. Yehya N. Graham K. Kilbaugh T. Berg R. A. Topjian A. (2020 ). Circulating Neurofilament Light Chain Is Associated With Survival After Pediatric Cardiac Arrest. Pediatr. Crit. Care Med. 21 656–661.

    Not in our library10.1097/pcc.0000000000002294

  144. 144.

    Kleijmeer M. Ramm G. Schuurhuis D. Griffith J. Rescigno M. Ricciardi-Castagnoli P. (2001 ). Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J. Cell Biol. 155 53–63.

    Not in our library10.1083/jcb.200103071

  145. 145.

    Koel-Simmelink M. J. Vennegoor A. Killestein J. Blankenstein M. A. Norgren N. Korth C. (2014 ). The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J. Immunol. Methods 402 43–49.

    Not in our library10.1016/j.jim.2013.11.008

  146. 146.

    Kohnken R. Buerger K. Zinkowski R. Miller C. Kerkman D. Debernardis J. (2000 ). Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 287 187–190.

    Not in our library10.1016/s0304-3940(00)01178-2

  147. 147.

    Korley F. K. Goldstick J. Mastali M. Van Eyk J. E. Barsan W. Meurer W. J. (2019 ). Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus. Stroke 50 1669–1675.

    Not in our library10.1161/strokeaha.119.024941

  148. 148.
    Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis · 2018
    Not checked
  149. 149.

    Kriz J. Zhu Q. Julien J. P. Padjen A. L. (2000 ). Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res. 885 32–44.

    Not in our library10.1016/s0006-8993(00)02899-7

  150. 150.

    Kuhle J. Barro C. Disanto G. Mathias A. Soneson C. Bonnier G. (2016 ). Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult. Scler. 22 1550–1559.

    Not in our library10.1177/1352458515623365

  151. 151.

    Kuhle J. Gaiottino J. Leppert D. Petzold A. Bestwick J. P. Malaspina A. (2015 ). Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J. Neurol. Neurosurg. Psychiatry 86 273–279.

    Not in our library10.1136/jnnp-2013-307454

  152. 152.

    Kuhle J. Kropshofer H. Haering D. A. Kundu U. Meinert R. Barro C. (2019 ). Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurol. 92 e1007–e1015.

    Not in our library10.1212/wnl.0000000000007032

  153. 153.

    Kuhle J. Malmestrom C. Axelsson M. Plattner K. Yaldizli O. Derfuss T. (2013 ). Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol. Scand. 128 e33–e36.

    Not in our library10.1111/ane.12151

  154. 154.

    Kuhle J. Regeniter A. Leppert D. Mehling M. Kappos L. Lindberg R. L. (2010 ). A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J. Neuroimmunol. 220 114–119.

    Not in our library10.1016/j.jneuroim.2010.01.004

  155. 155.

    Lachenal G. Pernet-Gallay K. Chivet M. Hemming F. J. Belly A. Bodon G. (2011 ). Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol. Cell Neurosci. 46 409–418.

    Not in our library10.1016/j.mcn.2010.11.004

  156. 156.
    Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline · 2020
    No notice
  157. 157.

    Lariviere R. C. Nguyen M. D. Ribeiro-Da-Silva A. Julien J. P. (2002 ). Reduced number of unmyelinated sensory axons in peripherin null mice. J. Neurochem. 81 525–532.

    Not in our library10.1046/j.1471-4159.2002.00853.x

  158. 158.

    Lee M. K. Marszalek J. R. Cleveland D. W. (1994 ). A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 13 975–988.

    Not in our library10.1016/0896-6273(94)90263-1

  159. 159.

    Lendahl U. Zimmerman L. B. Mckay R. D. (1990 ). CNS stem cells express a new class of intermediate filament protein. Cell 60 585–595.

    Not in our library10.1016/0092-8674(90)90662-x

  160. 160.

    Lerat J. Magdelaine C. Beauvais-Dzugan H. Espil C. Ghorab K. Latour P. (2019 ). A novel pathogenic variant of NEFL responsible for deafness associated with peripheral neuropathy discovered through next-generation sequencing and review of the literature. J. Peripher. Nerv. Syst. 24 139–144.

    Not in our library10.1111/jns.12310

  161. 161.
    Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease · 2018
    No notice
  162. 162.

    Lewczuk P. Esselmann H. Bibl M. Beck G. Maler J. M. Otto M. (2004 ). Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J. Mol. Neurosci. 23 115–122.

    Not in our library10.1385/jmn:23:1-2:115

  163. 163.

    Lewis S. B. Wolper R. A. Miralia L. Yang C. Shaw G. (2008 ). Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage patients. J. Cereb. Blood Flow Metab. 28 1261–1271.

    Not in our library10.1038/jcbfm.2008.12

  164. 164.

    Li D. Zhang L. Nelson N. W. Mielke M. M. Yu F. (2021 ). Plasma neurofilament light and future declines in cognition and function in Alzheimer’s disease in the FIT-AD trial. J. Alzheimers Dis. Rep. 5 601–611.

    Not in our library10.3233/adr-210302

  165. 165.

    Li Q. F. Dong Y. Yang L. Xie J. J. Ma Y. Du Y. C. (2019 ). Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. Mol. Neurodegener. 14:39.

    Not in our library10.1186/s13024-019-0338-0

  166. 166.

    Liang Y. Tong F. Zhang L. Zhu L. Li W. Huang W. (2019 ). iTRAQ-based proteomic analysis discovers potential biomarkers of diffuse axonal injury in rats. Brain Res. Bull. 153 289–304.

    Not in our library10.1016/j.brainresbull.2019.09.004

  167. 167.

    Lin C. H. Li C. H. Yang K. C. Lin F. J. Wu C. C. Chieh J. J. (2019 ). Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology 93 e1104–e1111.

    Not in our library10.1212/wnl.0000000000008088

  168. 168.

    Lin X. Lu T. Deng H. Liu C. Yang Y. Chen T. (2021 ). Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases. J. Neurol. [Preprint].

    Not in our library10.1007/s00415-021-10660-0

  169. 169.
    Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease · 2018
    No notice
  170. 170.

    Linker R. A. Brechlin P. Jesse S. Steinacker P. Lee D. H. Asif A. R. (2009 ). Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One 4:e7624.

    Not in our library10.1371/journal.pone.0007624

  171. 171.

    Liu C. Zhao L. Fan P. Ko H. Au C. Ng A. (2021 ). High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders. J. Clin. Neurosci. 83 108–111.

    Not in our library10.1016/j.jocn.2020.11.016

  172. 172.
    Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology. · 2020
    Not checked
  173. 173.

    Liu Q. Xie F. Alvarado-Diaz A. Smith M. A. Moreira P. I. Zhu X. (2011 ). Neurofilamentopathy in neurodegenerative diseases. Open Neurol. J. 5 58–62.

    Not in our library10.2174/1874205x01105010058

  174. 174.

    Liu S. Huang Z. Zhang L. Pan J. Lei Q. Meng Y. (2020 ). Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases. Front. Aging Neurosci. 12:10.

    Not in our library10.3389/fnagi.2020.00010

  175. 175.

    Llibre-Guerra J. J. Li Y. Schindler S. E. Gordon B. A. Fagan A. M. Morris J. C. (2019 ). Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Netw. Open 2:e1917126.

    Not in our library10.1001/jamanetworkopen.2019.17126

  176. 176.

    Lombardi V. Carassiti D. Giovannoni G. Lu C. H. Adiutori R. Malaspina A. (2020 ). The potential of neurofilaments analysis using dry-blood and plasma spots. Sci. Rep. 10:97.

    Not in our library10.1038/s41598-019-54310-y

  177. 177.

    Lomen-Hoerth C. (2011 ). Clinical phenomenology and neuroimaging correlates in ALS-FTD. J. Mol. Neurosci. 45 656–662.

    Not in our library10.1007/s12031-011-9636-x

  178. 178.

    Lu C. H. Macdonald-Wallis C. Gray E. Pearce N. Petzold A. Norgren N. (2015 ). Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84 2247–2257.

    Not in our library10.1212/wnl.0000000000001642

  179. 179.

    Lu C. H. Petzold A. Kalmar B. Dick J. Malaspina A. Greensmith L. (2012 ). Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 7:e40998.

    Not in our library10.1371/journal.pone.0040998

  180. 180.

    Ma L. Z. Zhang C. Wang H. Ma Y. H. Shen X. N. Wang J. (2021 ). Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson’s Disease. J. Parkinsons Dis. [Preprint].

    Not in our library10.3233/jpd-212535

  181. 181.

    Mages B. Aleithe S. Altmann S. Blietz A. Nitzsche B. Barthel H. (2018 ). Impaired Neurofilament Integrity and Neuronal Morphology in Different Models of Focal Cerebral Ischemia and Human Stroke Tissue. Front. Cell Neurosci. 12:161.

    Not in our library10.3389/fncel.2018.00161

  182. 182.

    Maggi P. Kuhle J. Schadelin S. Van Der Meer F. Weigel M. Galbusera R. (2021 ). Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology 97 e543–e553.

    Not in our library10.1212/wnl.0000000000012326

  183. 183.
    Confounding effect of blood volume and body mass index on blood neurofilament light chain levels · 2020
    No notice
  184. 184.

    Mariotto S. Farinazzo A. Magliozzi R. Alberti D. Monaco S. Ferrari S. (2018 ). Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J. Peripher. Nerv. Syst. 23 174–177.

    Not in our library10.1111/jns.12279

  185. 185.

    Martinez-Morillo E. Childs C. Garcia B. P. Alvarez Menendez F. V. Romaschin A. D. Cervellin G. (2015 ). Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. Clin. Chem. Lab. Med. 53 1575–1584.

    Not in our library10.1515/cclm-2014-0908

  186. 186.

    Martinez-Morillo E. Garcia Hernandez P. Begcevic I. Kosanam H. Prieto Garcia B. Alvarez Menendez F. V. (2014 ). Identification of novel biomarkers of brain damage in patients with hemorrhagic stroke by integrating bioinformatics and mass spectrometry-based proteomics. J. Proteome Res. 13 969–981.

    Not in our library10.1021/pr401111h

  187. 187.
    Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease · 2017
    No notice
  188. 188.

    Mayeli M. Mirshahvalad S. M. Aghamollaii V. Tafakhori A. Abdolalizadeh A. Rahmani F. (2019 ). Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions. J. Neuropathol. Exp. Neurol. [Preprint].

    Not in our library10.1093/jnen/nlz054

  189. 189.

    McDonald S. J. O’brien W. T. Symons G. F. Chen Z. Bain J. Major B. P. (2021 ). Prolonged elevation of serum neurofilament light after concussion in male Australian football players. Biomark Res. 9:4.

    Not in our library10.1186/s40364-020-00256-7

  190. 190.
    In Vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer’s Aβ protein · 2016
    Not checked
  191. 191.
    Neurofilament light chain: a biomarker for genetic frontotemporal dementia · 2016
    No notice
  192. 192.

    Merluzzi A. P. Vogt N. M. Norton D. Jonaitis E. Clark L. R. Carlsson C. M. (2019 ). Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimers Dement. 5 129–138.

    Not in our library10.1016/j.trci.2019.02.004

  193. 193.

    Mielke M. M. Hagen C. E. Xu J. Chai X. Vemuri P. Lowe V. J. (2018 ). Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14 989–997.

    Not in our library10.1016/j.jalz.2018.02.013

  194. 194.

    Mietani K. Sumitani M. Ogata T. Shimojo N. Inoue R. Abe H. (2019 ). Dysfunction of the blood-brain barrier in postoperative delirium patients, referring to the axonal damage biomarker phosphorylated neurofilament heavy subunit. PLoS One 14:e0222721.

    Not in our library10.1371/journal.pone.0222721

  195. 195.

    Miller T. Cudkowicz M. Shaw P. J. Andersen P. M. Atassi N. Bucelli R. C. (2020 ). Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 383 109–119.

    Not in our library10.1056/nejmoa2003715

  196. 196.

    Millere E. Rots D. Simren J. Ashton N. J. Kupats E. Micule I. (2021 ). Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur. J. Neurol. 28 974–981.

    Not in our library10.1111/ene.14689

  197. 197.
    Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints · 2020
    No notice
  198. 198.

    Miyazawa I. Nakashima I. Petzold A. Fujihara K. Sato S. Itoyama Y. (2007 ). High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 68 865–867.

    Not in our library10.1212/01.wnl.0000256820.26489.17

  199. 199.

    Moore E. E. Hohman T. J. Badami F. S. Pechman K. R. Osborn K. E. Acosta L. M. Y. (2018 ). Neurofilament relates to white matter microstructure in older adults. Neurobiol. Aging 70 233–241.

    Not in our library10.1016/j.neurobiolaging.2018.06.023

  200. 200.
    The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson’s disease brain as revealed by multicolor STED microscopy · 2021
    No notice
  201. 201.
    Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease · 2021
    No notice
  202. 202.

    Moscoso A. Grothe M. J. Ashton N. J. Karikari T. K. Rodriguez J. L. Snellman A. (2021b ). Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum. Brain 144 325–339.

    Not in our library10.1093/brain/awaa399

  203. 203.

    Moseby-Knappe M. Mattsson N. Nielsen N. Zetterberg H. Blennow K. Dankiewicz J. (2019 ). Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurol. 76 64–71.

    Not in our library10.1001/jamaneurol.2018.3223

  204. 204.

    Mucke N. Kammerer L. Winheim S. Kirmse R. Krieger J. Mildenberger M. (2018 ). Assembly Kinetics of Vimentin Tetramers to Unit-Length Filaments: A Stopped-Flow Study. Biophys. J. 114 2408–2418.

    Not in our library10.1016/j.bpj.2018.04.032

  205. 205.

    Muller-Wielsch K. Cannella B. Raine C. S. (2017 ). Multiple sclerosis: neurofilament pathology in spinal motor neurons. J. Mult. Scler. 04:1000207.

    Not in our library10.4172/2376-0389.1000207

  206. 206.

    Murphy A. Breen K. C. Long A. Feighery C. Casey E. B. Kelleher D. (1993 ). Neurofilament expression in human T lymphocytes. Immunology 79 167–170.

    Not in our library

  207. 207.

    Natori A. Ogata T. Sumitani M. Kogure T. Yamauchi T. Yamauchi H. (2015 ). Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment. Clin. Cancer Res. 21 1348–1352.

    Not in our library10.1158/1078-0432.ccr-14-2775

  208. 208.
    Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease? · 2017
    Not checked
  209. 209.

    Nilsson I. A. K. Millischer V. Karrenbauer V. D. Jureus A. Salehi A. M. Norring C. (2019 ). Plasma neurofilament light chain concentration is increased in anorexia nervosa. Transl. Psychiatry 9:180.

    Not in our library10.1038/s41398-019-0518-2

  210. 210.

    Nishida H. Nakayama M. Tanaka H. Kamishina H. Izawa T. Hatoya S. (2014 ). Evaluation of serum phosphorylated neurofilament subunit NF-H as a prognostic biomarker in dogs with thoracolumbar intervertebral disc herniation. Vet. Surg. 43 289–293.

    Not in our library10.1111/j.1532-950x.2014.12144.x

  211. 211.

    Nixon R. A. Logvinenko K. B. (1986 ). Multiple fates of newly synthesized neurofilament proteins: evidence for a stationary neurofilament network distributed nonuniformly along axons of retinal ganglion cell neurons. J. Cell Biol. 102 647–659.

    Not in our library10.1083/jcb.102.2.647

  212. 212.

    Nixon R. A. Marotta C. A. (1984 ). Degradation of neurofilament proteins by purified human brain cathepsin D. J. Neurochem. 43 507–516.

    Not in our library10.1111/j.1471-4159.1984.tb00928.x

  213. 213.

    Nixon R. A. Paskevich P. A. Sihag R. K. Thayer C. Y. (1994 ). Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo: influences on regional neurofilament accumulation, interneurofilament spacing, and axon caliber. J. Cell Biol. 126 1031–1046.

    Not in our library10.1083/jcb.126.4.1031

  214. 214.

    Norgren N. Karlsson J. E. Rosengren L. Stigbrand T. (2002 ). Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics 21 53–59.

    Not in our library10.1089/15368590252917647

  215. 215.

    Norgren N. Rosengren L. Stigbrand T. (2003 ). Elevated neurofilament levels in neurological diseases. Brain Res. 987 25–31.

    Not in our library10.1016/s0006-8993(03)03219-0

  216. 216.
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein · 2017
    No notice
  217. 217.

    Nylen K. Csajbok L. Z. Ost M. Rashid A. Karlsson J. E. Blennow K. (2006 ). CSF -neurofilament correlates with outcome after aneurysmal subarachnoid hemorrhage. Neurosci. Lett. 404 132–136.

    Not in our library10.1016/j.neulet.2006.05.029

  218. 218.

    O’connor A. Karikari T. K. Poole T. Ashton N. J. Lantero Rodriguez J. Khatun A. (2020 ). Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Mol. Psychiatry [Preprint].

    Not in our library10.1038/s41380-020-0838-x

  219. 219.

    O”Brien W. T. Pham L. Brady R. D. Bain J. Yamakawa G. R. Sun M. (2021 ). Temporal profile and utility of serum neurofilament light in a rat model of mild traumatic brain injury. Exp. Neurol. 341:113698.

    Not in our library10.1016/j.expneurol.2021.113698

  220. 220.
    NFL is a marker of treatment response in children with SMA treated with nusinersen · 2019
    No notice
  221. 221.

    Olsson B. Lautner R. Andreasson U. Ohrfelt A. Portelius E. Bjerke M. (2016 ). CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 15 673–684.

    Not in our library10.1016/s1474-4422(16)00070-3

  222. 222.

    Osborn K. E. Khan O. A. Kresge H. A. Bown C. W. Liu D. Moore E. E. (2019 ). Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimers Dement. 11 700–709.

    Not in our library10.1016/j.dadm.2019.08.008

  223. 223.

    Pachter J. S. Liem R. K. (1984 ). The differential appearance of neurofilament triplet polypeptides in the developing rat optic nerve. Dev. Biol. 103 200–210.

    Not in our library10.1016/0012-1606(84)90021-6

  224. 224.

    Palmqvist S. Janelidze S. Quiroz Y. T. Zetterberg H. Lopera F. Stomrud E. (2020 ). Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 324 772–781.

    Not in our library10.1001/jama.2020.12134

  225. 225.

    Pant H. C. (1988 ). Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem. J. 256 665–668.

    Not in our library10.1042/bj2560665

  226. 226.

    Paterson R. W. Gabelle A. Lucey B. P. Barthelemy N. R. Leckey C. A. Hirtz C. (2019 ). SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. Nat. Rev. Neurol. 15 419–427.

    Not in our library10.1038/s41582-019-0222-0

  227. 227.

    Peikert K. Akgun K. Beste C. Ziemssen T. Buhmann C. Danek A. (2020 ). Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. Parkinsonism Relat. Disord. 80 28–31.

    Not in our library10.1016/j.parkreldis.2020.09.004

  228. 228.

    Peng Y. Li Q. Qin L. He Y. Luo X. Lan Y. (2021 ). Combination of Serum Neurofilament Light Chain Levels and MRI Markers to Predict Cognitive Function in Ischemic Stroke. Neurorehabil. Neural Repair 2021:1545968321989354.

    Not in our library10.1177/1545968321989354

  229. 229.

    Peng Y. Zhang Y. Chen Z. Peng H. Wan N. Zhang J. (2020 ). Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3. Neurology 95 e2977–e2987.

    Not in our library10.1212/wnl.0000000000010671

  230. 230.

    Pereira J. B. Westman E. Hansson O. Alzheimer’s Disease Neuroimaging I. (2017 ). Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol. Aging 58 14–29.

    Not in our library10.1016/j.neurobiolaging.2017.06.002

  231. 231.

    Perez-Olle R. Leung C. L. Liem R. K. (2002 ). Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J. Cell Sci. 115 4937–4946.

    Not in our library10.1242/jcs.00148

  232. 232.

    Perino J. Patterson M. Momen M. Borisova M. Heslegrave A. Zetterberg H. (2021 ). Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog. Neurosci. Lett. 744:135593.

    Not in our library10.1016/j.neulet.2020.135593

  233. 233.
    Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease · 2020
    Not checked
  234. 234.

    Petersen M. E. Rafii M. S. Zhang F. Hall J. Julovich D. Ances B. M. (2021 ). Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. J. Alzheimers Dis. 79 671–681.

    Not in our library10.3233/jad-201167

  235. 235.

    Petrova N. Carassiti D. Altmann D. R. Baker D. Schmierer K. (2018 ). Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol. 28 334–348.

    Not in our library10.1111/bpa.12516

  236. 236.

    Petzold A. Keir G. Green A. J. Giovannoni G. Thompson E. J. (2003 ). A specific ELISA for measuring neurofilament heavy chain phosphoforms. J. Immunol. Methods 278 179–190.

    Not in our library10.1016/s0022-1759(03)00189-3

  237. 237.

    Piepgras J. Muller A. Steffen F. Lotz J. Loquai C. Zipp F. (2021 ). Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy. Eur. J. Neurol. 28 1086–1089.

    Not in our library10.1111/ene.14692

  238. 238.

    Pijnenburg Y. A. Verwey N. A. Van Der Flier W. M. Scheltens P. Teunissen C. E. (2015 ). Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. 1 505–512.

    Not in our library10.1016/j.dadm.2015.11.001

  239. 239.

    Pilotto A. Imarisio A. Carrarini C. Russo M. Masciocchi S. Gipponi S. (2021 ). Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. J. Alzheimers Dis. 82 913–919.

    Not in our library10.3233/jad-210342

  240. 240.

    Pisciotta C. Bai Y. Brennan K. M. Wu X. Grider T. Feely S. (2015 ). Reduced neurofilament expression in cutaneous nerve fibers of patients with CMT2E. Neurology 85 228–234.

    Not in our library10.1212/wnl.0000000000001773

  241. 241.

    Poesen K. De Schaepdryver M. Stubendorff B. Gille B. Muckova P. Wendler S. (2017 ). Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88 2302–2309.

    Not in our library10.1212/wnl.0000000000004029

  242. 242.

    Price R. W. Brew B. J. (1988 ). The AIDS dementia complex. J. Infect Dis. 158 1079–1083.

    Not in our library10.1093/infdis/158.5.1079

  243. 243.

    Pujol-Calderon F. Portelius E. Zetterberg H. Blennow K. Rosengren L. E. Hoglund K. (2019 ). Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci. Lett. 698 58–63.

    Not in our library10.1016/j.neulet.2018.12.042

  244. 244.

    Qiao X. Zhang S. Zhao W. Ye H. Yang Y. Zhang Z. (2015 ). Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes. Medicine 94:e1908.

    Not in our library10.1097/md.0000000000001908

  245. 245.

    Qu Y. Tan C. C. Shen X. N. Li H. Q. Cui M. Tan L. (2021 ). Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly: A Longitudinal Study. Stroke 2021:STROKEAHA120030302.

    Not in our library10.1161/strokeaha.120.030302

  246. 246.

    Quiroz Y. T. Zetterberg H. Reiman E. M. Chen Y. Su Y. Fox-Fuller J. T. (2020 ). Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol. 19 513–521.

    Not in our library10.1016/s1474-4422(20)30137-x

  247. 247.

    Rana O. R. Schroder J. W. Baukloh J. K. Saygili E. Mischke K. Schiefer J. (2013 ). Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int. J. Cardiol. 168 1322–1327.

    Not in our library10.1016/j.ijcard.2012.12.016

  248. 248.

    Rao M. V. Yuan A. Campbell J. Kumar A. Nixon R. A. (2012 ). The C-terminal domains of NF-H and NF-M subunits maintain axonal neurofilament content by blocking turnover of the stationary neurofilament network. PLoS One 7:e44320.

    Not in our library10.1371/journal.pone.0044320

  249. 249.

    Rasmussen M. K. Mestre H. Nedergaard M. (2018 ). The glymphatic pathway in neurological disorders. Lancet Neurol. 17 1016–1024.

    Not in our library10.1016/s1474-4422(18)30318-1

  250. 250.

    Reinert M. C. Benkert P. Wuerfel J. Michalak Z. Ruberte E. Barro C. (2020 ). Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 7:e749.

    Not in our library10.1212/nxi.0000000000000749

  251. 251.

    Rejdak K. Kuhle J. Ruegg S. Lindberg R. L. Petzold A. Sulejczak D. (2012 ). Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury. Epilepsia 53 922–927.

    Not in our library10.1111/j.1528-1167.2012.03459.x

  252. 252.

    Remnestal J. Oijerstedt L. Ullgren A. Olofsson J. Bergstrom S. Kultima K. (2020 ). Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Transl. Neurodegener. 9:27.

    Not in our library10.1186/s40035-020-00198-y

  253. 253.

    Rissin D. M. Kan C. W. Campbell T. G. Howes S. C. Fournier D. R. Song L. (2010 ). Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28 595–599.

    Not in our library10.1038/nbt.1641

  254. 254.

    Robinson C. A. Clark A. W. Parhad I. M. Fung T. S. Bou S. S. (1994 ). Gene expression in Alzheimer neocortex as a function of age and pathologic severity. Neurobiol. Aging 15 681–690.

    Not in our library10.1016/0197-4580(94)90049-3

  255. 255.

    Rodrigues F. B. Byrne L. M. Tortelli R. Johnson E. B. Wijeratne P. A. Arridge M. (2020 ). Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease. Sci. Transl. Med. 12:eabc2888.

    Not in our library10.1126/scitranslmed.abc2888

  256. 256.
    Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia · 2016
    No notice
  257. 257.

    Rosen C. Rosen H. Andreasson U. Bremell D. Bremler R. Hagberg L. (2014 ). Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation 85 227–232.

    Not in our library10.1016/j.resuscitation.2013.10.032

  258. 258.

    Rosen H. Karlsson J. E. Rosengren L. (2004 ). CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J. Neurol. Sci. 221 19–24.

    Not in our library10.1016/j.jns.2004.03.003

  259. 259.

    Rosengren L. E. Karlsson J. E. Karlsson J. O. Persson L. I. Wikkelso C. (1996 ). Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 67 2013–2018.

    Not in our library10.1046/j.1471-4159.1996.67052013.x

  260. 260.

    Rossi D. Volanti P. Brambilla L. Colletti T. Spataro R. La Bella V. (2018 ). CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 265 510–521.

    Not in our library10.1007/s00415-017-8730-6

  261. 261.
    Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis · 2020
    Not checked
  262. 262.

    Ru Y. Corado C. Soon R. K. Jr. Melton A. C. Harris A. Yu G. K. (2019 ). Neurofilament light is a treatment-responsive biomarker in CLN2 disease. Ann. Clin. Transl. Neurol. 6 2437–2447.

    Not in our library10.1002/acn3.50942

  263. 263.

    Rudrabhatla P. Grant P. Jaffe H. Strong M. J. Pant H. C. (2010 ). Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer’s disease by iTRAQ. FASEB J. 24 4396–4407.

    Not in our library10.1096/fj.10-157859

  264. 264.

    Rudrabhatla P. Jaffe H. Pant H. C. (2011 ). Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer’s NFTs. FASEB J. 25 3896–3905.

    Not in our library10.1096/fj.11-181297

  265. 265.

    Sabbatini D. Raggi F. Ruggero S. Seguso M. Mandrioli J. Cagnin A. (2021 ). Evaluation of peripherin in biofluids of patients with motor neuron diseases. Ann. Clin. Transl. Neurol. 8 1750–1754.

    Not in our library10.1002/acn3.51419

  266. 266.

    Sainio M. T. Ylikallio E. Maenpaa L. Lahtela J. Mattila P. Auranen M. (2018 ). Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy. Neurol. Genet. 4:e244.

    Not in our library10.1212/nxg.0000000000000244

  267. 267.

    Sanchez I. Hassinger L. Paskevich P. A. Shine H. D. Nixon R. A. (1996 ). Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J. Neurosci. 16 5095–5105.

    Not in our library10.1523/jneurosci.16-16-05095.1996

  268. 268.
    Plasma neurofilament light chain concentration in the inherited peripheral neuropathies · 2018
    No notice
  269. 269.

    Santangelo R. Agosta F. Masi F. Spinelli E. G. Cecchetti G. Caso F. (2021 ). Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer’s disease. Eur. J. Neurol. 28 2980–2988.

    Not in our library10.1111/ene.14999

  270. 270.

    Sara M. Matteo G. Luisa G. Chiara M. Ruggero C. Romain M. (2021 ). NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. Mult. Scler. Relat. Disord. 50:102833.

    Not in our library10.1016/j.msard.2021.102833

  271. 271.

    Saraste M. Bezukladova S. Matilainen M. Tuisku J. Rissanen E. Sucksdorff M. (2021 ). High serum neurofilament associates with diffuse white matter damage in MS. Neurol. Neuroimmunol. Neuroinflamm. 8:e926.

    Not in our library10.1212/nxi.0000000000000926

  272. 272.

    Sato C. Barthelemy N. R. Mawuenyega K. G. Patterson B. W. Gordon B. A. Jockel-Balsarotti J. (2018 ). Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98 861–864.

    Not in our library10.1016/j.neuron.2018.04.035

  273. 273.
    Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis · 2020
    No notice
  274. 274.

    Schulz A. Ajayi T. Specchio N. De Los Reyes E. Gissen P. Ballon D. (2018 ). Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N. Engl. J. Med. 378 1898–1907.

    Not in our library10.1056/nejmoa1712649

  275. 275.
    Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two-hit” model · 2017
    No notice
  276. 276.

    Shabanzadeh A. P. D’onofrio P. M. Monnier P. P. Koeberle P. D. (2015 ). Targeting caspase-6 and caspase-8 to promote neuronal survival following ischemic stroke. Cell Death Dis. 6:e1967.

    Not in our library10.1038/cddis.2015.272

  277. 277.
    Serum neurofilament light protein predicts clinical outcome in traumatic brain injury · 2016
    No notice
  278. 278.

    Shahim P. Politis A. Van Der Merwe A. Moore B. Chou Y. Y. Pham D. L. (2020 ). Neurofilament light as a biomarker in traumatic brain injury. Neurology 95 e610–e622.

    Not in our library10.1212/wnl.0000000000009983

  279. 279.

    Shahim P. Zetterberg H. Tegner Y. Blennow K. (2017 ). Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88 1788–1794.

    Not in our library10.1212/wnl.0000000000003912

  280. 280.

    Shaw G. Weber K. (1982 ). Differential expression of neurofilament triplet proteins in brain development. Nature 298 277–279.

    Not in our library10.1038/298277a0

  281. 281.

    Shaw G. Yang C. Ellis R. Anderson K. Parker Mickle J. Scheff S. (2005 ). Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem. Biophys. Res. Commun. 336 1268–1277.

    Not in our library10.1016/j.bbrc.2005.08.252

  282. 282.

    Shekhar S. Kumar R. Rai N. Kumar V. Singh K. Upadhyay A. D. (2016 ). Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients. PLoS One 11:e0159099.

    Not in our library10.1371/journal.pone.0159099

  283. 283.

    Shen H. Barry D. M. Dale J. M. Garcia V. B. Calcutt N. A. Garcia M. L. (2011 ). Muscle pathology without severe nerve pathology in a new mouse model of Charcot-Marie-Tooth disease type 2E. Hum. Mol. Genet. 20 2535–2548.

    Not in our library10.1093/hmg/ddr152

  284. 284.

    Shibahashi K. Doi T. Tanaka S. Hoda H. Chikuda H. Sawada Y. (2016 ). The Serum Phosphorylated Neurofilament Heavy Subunit as a Predictive Marker for Outcome in Adult Patients after Traumatic Brain Injury. J. Neurotrauma 33 1826–1833.

    Not in our library10.1089/neu.2015.4237

  285. 285.

    Shinomoto M. Kasai T. Tatebe H. Kondo M. Ohmichi T. Morimoto M. (2019 ). Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PLoS One 14:e0211575.

    Not in our library10.1371/journal.pone.0211575

  286. 286.

    Shribman S. Heller C. Burrows M. Heslegrave A. Swift I. Foiani M. S. (2021 ). Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson’s Disease. Mov. Disord. 36 503–508.

    Not in our library10.1002/mds.28333

  287. 287.

    Singh A. Kumar V. Ali S. Mahdi A. A. Srivastava R. N. (2017 ). Phosphorylated neurofilament heavy: A potential blood biomarker to evaluate the severity of acute spinal cord injuries in adults. Int. J. Crit. Illn. Inj. Sci. 7 212–217.

    Not in our library10.4103/ijciis.ijciis_73_16

  288. 288.

    Singh P. Yan J. Hull R. Read S. O’sullivan J. Henderson R. D. (2011 ). Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. J. Neurol. Sci. 304 117–121.

    Not in our library10.1016/j.jns.2011.01.025

  289. 289.

    Skillback T. Farahmand B. Bartlett J. W. Rosen C. Mattsson N. Nagga K. (2014 ). CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83 1945–1953.

    Not in our library10.1212/wnl.0000000000001015

  290. 290.

    Skillback T. Mattsson N. Blennow K. Zetterberg H. (2017 ). Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph. Lateral Scler. Frontotemporal Degener. 18 397–403.

    Not in our library10.1080/21678421.2017.1281962

  291. 291.

    Smerjac S. M. Zheng J. Hu C. L. Bizzozero O. A. (2018 ). The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis. Neurochem. Res. 43 2277–2287.

    Not in our library10.1007/s11064-018-2648-y

  292. 292.

    Sofou K. Shahim P. Tulinius M. Blennow K. Zetterberg H. Mattsson N. (2019 ). Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion 46 228–235.

    Not in our library10.1016/j.mito.2018.07.002

  293. 293.

    Soylu-Kucharz R. Sandelius A. Sjogren M. Blennow K. Wild E. J. Zetterberg H. (2017 ). Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice. Sci. Rep. 7:14114.

    Not in our library10.1038/s41598-017-14179-1

  294. 294.

    Spotorno N. Lindberg O. Nilsson C. Landqvist Waldo M. Van Westen D. Nilsson K. (2020 ). Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. PLoS One 15:e0236384.

    Not in our library10.1371/journal.pone.0236384

  295. 295.

    Steinacker P. Blennow K. Halbgebauer S. Shi S. Ruf V. Oeckl P. (2016 ). Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci. Rep. 6:38737.

    Not in our library10.1038/srep38737

  296. 296.

    Strydom A. Heslegrave A. Startin C. M. Mok K. Y. Hardy J. Groet J. (2018 ). Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res. Ther. 10:39.

    Not in our library10.1186/s13195-018-0367-x

  297. 297.
    Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected · 2020
    No notice
  298. 298.

    Sun B. Dalvi P. Abadjian L. Tang N. Pulliam L. (2017 ). Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS 31 F9–F17.

    Not in our library10.1097/qad.0000000000001595

  299. 299.

    Sutter R. Hert L. De Marchis G. M. Twerenbold R. Kappos L. Naegelin Y. (2021 ). Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann. Neurol. 89 610–616.

    Not in our library10.1002/ana.26004

  300. 300.

    Sweeney M. D. Sagare A. P. Zlokovic B. V. (2018 ). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14 133–150.

    Not in our library10.1038/nrneurol.2017.188

  301. 301.

    Szentistvanyi I. Patlak C. S. Ellis R. A. Cserr H. F. (1984 ). Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246 F835–F844.

    Not in our library10.1152/ajprenal.1984.246.6.f835

  302. 302.

    Szilasiova J. Mikula P. Rosenberger J. Fedicova M. Gdovinova Z. Urban P. (2021 ). Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss. Mult. Scler. 2021:1352458521998039.

    Not in our library10.1177/1352458521998039

  303. 303.

    Takahashi N. Ishizuka B. (2012 ). The involvement of neurofilament heavy chain phosphorylation in the maturation and degeneration of rat oocytes. Endocrinology 153 1990–1998.

    Not in our library10.1210/en.2011-2026

  304. 304.

    Tallantyre E. C. Bo L. Al-Rawashdeh O. Owens T. Polman C. H. Lowe J. (2009 ). Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132 1190–1199.

    Not in our library10.1093/brain/awp106

  305. 305.

    Tang W. Huang Q. Yao Y. Y. Wang Y. Wu Y. L. Wang Z. Y. (2014 ). Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J. Neural. Transm. 121 1541–1553.

    Not in our library10.1007/s00702-014-1226-y

  306. 306.

    Terasawa K. Taguchi T. Momota R. Naito I. Murakami T. Ohtsuka A. (2006 ). Human erythrocytes possess a cytoplasmic endoskeleton containing beta-actin and neurofilament protein. Arch. Histol. Cytol. 69 329–340.

    Not in our library10.1679/aohc.69.329

  307. 307.
    Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis · 2020
    No notice
  308. 308.

    Thebault S. Booth R. A. Rush C. A. Maclean H. Freedman M. S. (2021 ). Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. Front. Neurosci. 15:654942.

    Not in our library10.3389/fnins.2021.654942

  309. 309.

    Thebault S. Lee H. Bose G. Tessier D. Abdoli M. Bowman M. (2020b ). Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann. Clin. Transl. Neurol. 7 767–775.

    Not in our library10.1002/acn3.51045

  310. 310.

    Thijssen E. H. La Joie R. Wolf A. Strom A. Wang P. Iaccarino L. (2020 ). Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat. Med. 26 387–397.

    Not in our library10.1038/s41591-020-0762-2

  311. 311.

    Thompson A. G. B. Anastasiadis P. Druyeh R. Whitworth I. Nayak A. Nihat A. (2021 ). Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol. Psychiatry [Preprint].

    Not in our library10.1038/s41380-021-01045-w

  312. 312.

    Thompson A. G. B. Luk C. Heslegrave A. J. Zetterberg H. Mead S. H. Collinge J. (2018 ). Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J. Neurol. Neurosurg. Psychiatry 89 955–961.

    Not in our library10.1136/jnnp-2017-317793

  313. 313.

    Thouvenot E. Demattei C. Lehmann S. Maceski-Maleska A. Hirtz C. Juntas-Morales R. (2020 ). Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur. J. Neurol. 27 251–257.

    Not in our library10.1111/ene.14063

  314. 314.

    Ticau S. Sridharan G. V. Tsour S. Cantley W. L. Chan A. Gilbert J. A. (2019 ). Palsma proeome analysis of patients with hereditary transthyretin-mediated (hATTR) amyloidosis establishes neurofilament light chain (NfL) as a bimarker of disease and treatment response. medRxiv [Preprint].

    Not in our library10.1101/19011155

  315. 315.

    Tiedt S. Duering M. Barro C. Kaya A. G. Boeck J. Bode F. J. (2018 ). Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology 91 e1338–e1347.

    Not in our library10.1212/wnl.0000000000006282

  316. 316.
    Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease · 2021
    Not checked
  317. 317.

    Toft A. Roos P. Jaaskelainen O. Musaeus C. S. Henriksen E. E. Johannsen P. (2021 ). Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation. Dement. Geriatr. Cogn. Disord. 2021 1–6.

    Not in our library10.1159/000513877

  318. 318.

    Toorell H. Zetterberg H. Blennow K. Savman K. Hagberg H. (2018 ). Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. J. Matern Fetal Neonatal. Med. 31 2468–2472.

    Not in our library10.1080/14767058.2017.1344964

  319. 319.

    Tortelli R. Copetti M. Ruggieri M. Cortese R. Capozzo R. Leo A. (2015 ). Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur. J. Neurol. 22 215–218.

    Not in our library10.1111/ene.12421

  320. 320.

    Tradewell M. L. Durham H. D. Mushynski W. E. Gentil B. J. (2009 ). Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of charcot-marie-tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion. J. Neuropathol. Exp. Neurol. 68 642–652.

    Not in our library10.1097/nen.0b013e3181a5deeb

  321. 321.

    Van Der Ende E. L. Meeter L. H. Poos J. M. Panman J. L. Jiskoot L. C. Dopper E. G. P. (2019 ). Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 18 1103–1111.

    Not in our library10.1016/s1474-4422(19)30354-0

  322. 322.

    Van Der Plas E. Lullmann O. Hopkins L. Schultz J. L. Nopoulos P. C. Harshman L. A. (2021 ). Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease. Pediatr. Res. [Preprint].

    Not in our library10.1038/s41390-021-01649-6

  323. 323.

    Van Der Vuurst De Vries R. M. Wong Y. Y. M. Mescheriakova J. Y. Van Pelt E. D. Runia T. F. (2019 ). High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. Mult. Scler. 25 958–967.

    Not in our library10.1177/1352458518775303

  324. 324.

    Vanmechelen E. Vanderstichele H. Davidsson P. Van Kerschaver E. Van Der Perre B. Sjogren M. (2000 ). Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285 49–52.

    Not in our library10.1016/s0304-3940(00)01036-3

  325. 325.

    Vikartovska Z. Farbakova J. Smolek T. Hanes J. Zilka N. Hornakova L. (2020 ). Novel Diagnostic Tools for Identifying Cognitive Impairment in Dogs: Behavior, Biomarkers, and Pathology. Front. Vet. Sci. 7:551895.

    Not in our library10.3389/fvets.2020.551895

  326. 326.

    Von Bartheld C. S. Altick A. L. (2011 ). Multivesicular bodies in neurons: distribution, protein content, and trafficking functions. Prog. Neurobiol. 93 313–340.

    Not in our library10.1016/j.pneurobio.2011.01.003

  327. 327.

    Wang J. Hidaka T. Sasaki Y. Tanaka E. Takagi M. Shibata T. (2018 ). Neurofilament heavy polypeptide protects against reduction in synaptopodin expression and prevents podocyte detachment. Sci. Rep. 8:17157.

    Not in our library10.1038/s41598-018-35465-6

  328. 328.

    Wang J. H. Huang J. Guo F. Q. Wang F. Yang S. Yu N. W. (2021 ). Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment. Front. Aging Neurosci. 13:665981.

    Not in our library10.3389/fnagi.2021.665981

  329. 329.

    Wang Z. Wang R. Li Y. Li M. Zhang Y. Jiang L. (2021 ). Plasma Neurofilament Light Chain as a Predictive Biomarker for Post-stroke Cognitive Impairment: A Prospective Cohort Study. Front. Aging Neurosci. 13:631738.

    Not in our library10.3389/fnagi.2021.631738

  330. 330.
    Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy · 2021
    Not checked
  331. 331.

    Weydt P. Oeckl P. Huss A. Muller K. Volk A. E. Kuhle J. (2016 ). Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 79 152–158.

    Not in our library10.1002/ana.24552

  332. 332.

    Wihersaari L. Ashton N. J. Reinikainen M. Jakkula P. Pettila V. Hastbacka J. (2021 ). Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Med. 47 39–48.

    Not in our library10.1007/s00134-020-06218-9

  333. 333.

    Wilke C. Haas E. Reetz K. Faber J. Garcia-Moreno H. Santana M. M. (2020 ). Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol. Med. 12: e11803.

    Not in our library10.15252/emmm.201911803

  334. 334.

    Winston C. N. Romero H. K. Ellisman M. Nauss S. Julovich D. A. Conger T. (2019 ). Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity. Front. Neurosci. 13:1005.

    Not in our library10.3389/fnins.2019.01005

  335. 335.

    Winther-Larsen A. Hviid C. V. B. Meldgaard P. Sorensen B. S. Sandfeld-Paulsen B. (2020 ). Neurofilament Light Chain as A Biomarker for Brain Metastases. Cancers 12:2852.

    Not in our library10.3390/cancers12102852

  336. 336.

    Wong N. K. He B. P. Strong M. J. (2000 ). Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J. Neuropathol. Exp. Neurol. 59 972–982.

    Not in our library10.1093/jnen/59.11.972

  337. 337.

    Woolley J. D. Khan B. K. Murthy N. K. Miller B. L. Rankin K. P. (2011 ). The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J. Clin. Psychiatry 72 126–133.

    Not in our library10.4088/jcp.10m06382oli

  338. 338.

    Xiao S. Tjostheim S. Sanelli T. Mclean J. R. Horne P. Fan Y. (2008 ). An aggregate-inducing peripherin isoform generated through intron retention is upregulated in amyotrophic lateral sclerosis and associated with disease pathology. J. Neurosci. 28 1833–1840.

    Not in our library10.1523/jneurosci.3222-07.2008

  339. 339.

    Xu Z. Cork L. C. Griffin J. W. Cleveland D. W. (1993 ). Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73 23–33.

    Not in our library10.1016/0092-8674(93)90157-l

  340. 340.

    Yabe J. T. Chan W. K. Wang F. S. Pimenta A. Ortiz D. D. Shea T. B. (2003 ). Regulation of the transition from vimentin to neurofilaments during neuronal differentiation. Cell Motil. Cytoskeleton 56 193–205.

    Not in our library10.1002/cm.10137

  341. 341.

    Yamasaki H. Itakura C. Mizutani M. (1991 ). Hereditary hypotrophic axonopathy with neurofilament deficiency in a mutant strain of the Japanese quail. Acta Neuropathol. 82 427–434.

    Not in our library10.1007/bf00293376

  342. 342.

    Yan Y. Brown A. (2005 ). Neurofilament polymer transport in axons. J. Neurosci. 25 7014–7021.

    Not in our library10.1523/jneurosci.2001-05.2005

  343. 343.

    Yang Z. Zhu T. Mondello S. Akel M. Wong A. T. Kothari I. M. (2019 ). Serum-Based Phospho-Neurofilament-Heavy Protein as Theranostic Biomarker in Three Models of Traumatic Brain Injury: An Operation Brain Trauma Therapy Study. J. Neurotrauma 36 348–359.

    Not in our library10.1089/neu.2017.5586

  344. 344.

    Ye R. Locascio J. J. Goodheart A. E. Quan M. Zhang B. Gomperts S. N. (2021 ). Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: An 8-year longitudinal study. Parkinsonism Relat. Disord. 85 11–16.

    Not in our library10.1016/j.parkreldis.2021.02.008

  345. 345.

    Yilmaz A. Blennow K. Hagberg L. Nilsson S. Price R. W. Schouten J. (2017 ). Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev. Mol. Diagn. 17 761–770.

    Not in our library10.1080/14737159.2017.1341313

  346. 346.

    Yuan A. Hassinger L. Rao M. V. Julien J. P. Miller C. C. Nixon R. A. (2015a ). Dissociation of Axonal Neurofilament Content from Its Transport Rate. PLoS One 10:e0133848.

    Not in our library10.1371/journal.pone.0133848

  347. 347.

    Yuan A. Rao M. V. Kumar A. Julien J. P. Nixon R. A. (2003 ). Neurofilament transport in vivo minimally requires hetero-oligomer formation. J. Neurosci. 23 9452–9458.

    Not in our library10.1523/jneurosci.23-28-09452.2003

  348. 348.

    Yuan A. Rao M. V. Sasaki T. Chen Y. Kumar A. Veeranna (2006 ). Alpha-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. J. Neurosci. 26 10006–10019.

    Not in our library10.1523/jneurosci.2580-06.2006

  349. 349.

    Yuan A. Rao M. V. Veeranna Nixon R. A. (2017 ). Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb. Perspect. Biol. 9:a018309.

    Not in our library10.1101/cshperspect.a018309

  350. 350.

    Yuan A. Sasaki T. Kumar A. Peterhoff C. M. Rao M. V. Liem R. K. (2012 ). Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J. Neurosci. 32 8501–8508.

    Not in our library10.1523/jneurosci.1081-12.2012

  351. 351.

    Yuan A. Sasaki T. Rao M. V. Kumar A. Kanumuri V. Dunlop D. S. (2009 ). Neurofilaments form a highly stable stationary cytoskeleton after reaching a critical level in axons. J. Neurosci. 29 11316–11329.

    Not in our library10.1523/jneurosci.1942-09.2009

  352. 352.

    Yuan A. Sershen H. Veeranna, Basavarajappa B. S. Kumar A. Hashim A. (2015b ). Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo. Mol. Psychiatry 20 986–994.

    Not in our library10.1038/mp.2015.45

  353. 353.

    Yuan A. Veeranna, Sershen H. Basavarajappa B. S. Smiley J. F. Hashim A. (2018 ). Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors. Transl. Psychiatry 8:167.

    Not in our library10.1038/s41398-018-0194-7

  354. 354.

    Yum S. W. Zhang J. Mo K. Li J. Scherer S. S. (2009 ). A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy. Ann. Neurol. 66 759–770.

    Not in our library10.1002/ana.21728

  355. 355.

    Zerr I. Villar-Pique A. Hermann P. Schmitz M. Varges D. Ferrer I. (2021 ). Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res. Ther. 13:86.

    Not in our library10.1186/s13195-021-00815-6

  356. 356.

    Zetterberg H. Bozzetta E. Favole A. Corona C. Cavarretta M. C. Ingravalle F. (2019 ). Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS One 14:e0226697.

    Not in our library10.1371/journal.pone.0226697

  357. 357.

    Zetterberg H. Jacobsson J. Rosengren L. Blennow K. Andersen P. M. (2007 ). Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol. 14 1329–1333.

    Not in our library10.1111/j.1468-1331.2007.01972.x

  358. 358.

    Zetterberg H. Skillback T. Mattsson N. Trojanowski J. Q. Portelius E. Shaw L. M. (2016 ). Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 73 60–67.

    Not in our library10.1001/jamaneurol.2015.3037

  359. 359.

    Zhai J. Lin H. Julien J. P. Schlaepfer W. W. (2007 ). Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. Hum. Mol. Genet. 16 3103–3116.

    Not in our library10.1093/hmg/ddm272

  360. 360.

    Zhang M. Olsson Y. (1997 ). Hematogenous metastases of the human brain–characteristics of peritumoral brain changes: a review. J. Neurooncol. 35 81–89.

    Not in our library10.1023/a:1005799805335

  361. 361.

    Zhang N. Gu D. Meng M. Gordon M. L. (2020 ). TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer’s Disease. Front. Aging Neurosci. 12:166.

    Not in our library10.3389/fnagi.2020.00166

  362. 362.

    Zheng Y. S. Sun C. Wang R. Chen N. Luo S. S. Xi J. Y. (2021 ). Neurofilament light is a novel biomarker for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Sci. Rep. 11:2001.

    Not in our library10.1038/s41598-021-81721-7

  363. 363.

    Zhou W. Zhang J. Ye F. Xu G. Su H. Su Y. (2017 ). Plasma neurofilament light chain levels in Alzheimer’s disease. Neurosci. Lett. 650 60–64.

    Not in our library10.1016/j.neulet.2017.04.027

  364. 364.

    Zhu Q. Couillard-Despres S. Julien J. P. (1997 ). Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp. Neurol. 148 299–316.

    Not in our library10.1006/exnr.1997.6654

  365. 365.

    Zhu Y. Yang B. Wang F. Liu B. Li K. Yin K. (2021 ). Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson’s disease. J. Neuroimmunol. 358:577662.

    Not in our library10.1016/j.jneuroim.2021.577662

  366. 366.

    Zucchi E. Lu C. H. Cho Y. Chang R. Adiutori R. Zubiri I. (2018 ). A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J. Neurochem. 146 631–641.

    Not in our library10.1111/jnc.14542

  367. 367.

    Zuchner S. Vorgerd M. Sindern E. Schroder J. M. (2004 ). The novel neurofilament light (NEFL) mutation Glu397Lys is associated with a clinically and morphologically heterogeneous type of Charcot-Marie-Tooth neuropathy. Neuromuscul. Disord. 14 147–157.

    Not in our library10.1016/j.nmd.2003.10.003

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.